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Satellite cells are responsible for most of adult skeletal muscle regeneration. 
Upon activation they differentiate into transient amplifying myoblasts that 
undergo cell fusion to form multinucleated fibres. Despite their remarkable 
differentiation ability and the positive outcomes obtained with transplantation 
in dystrophic mice and recently in patients with oculo-pharyngeal muscular 
dystrophy (OPMD), clinical trials in patients with Duchenne muscular 
dystrophy (DMD) showed limited efficacy, mainly ascribed to myoblasts low 
survival and poor migration ability. Muscle pericyte-derived mesoangioblasts 
(perivascular cells associated to the capillaries) also contribute to muscle 
regeneration and colonise the satellite cell niche. These cells can be injected 
systemically and migrate through the vascular endothelium, circumventing the 
necessity of multiple intra-muscular injections. Mesoangioblasts have been 
also tested in a recently completed phase I / II clinical trial to assess their 
safety profile in five DMD patients (EudraCT no. 2011-000176-33). We 
hypothesise that exploiting the key properties of myoblasts and 
mesoangioblasts may have the potential to produce clinically relevant cells, 
superior to those currently available. This work shows that exposure to 
molecules involved in pericyte specification such as the Notch ligand DLL4 
and the growth factor PDGF-BB can induce direct reprogramming of primary 
satellite cells to pericyte-like cells. Reprogrammed cells acquire perivascular 
marker expression without losing the satellite cell marker Pax7. These highly 
myogenic cells can be expanded in culture and showed increased 
engraftment. In vitro and in vivo experiments also showed improved migration 
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ability, similar to what has been observed with mesoangioblasts. Additionally, 
this thesis includes a set of experiments aiming to assess the self-renewal 
potential of mesoangioblast-derived cells via serial transplantation assays. 
Overall, the results obtained improve our understanding of smooth / skeletal 
fate choice and self-renewal, providing evidence of the possibility of exploiting 
a direct reprogramming approach to allow systemic delivery of myoblasts for 
cell therapies of muscular dystrophies. 	  
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CHAPTER 1:  
1. INTRODUCTION  
1.1. The skeletal muscle tissue 
1.1.1. General architecture 
Striated skeletal muscle is the most abundant tissue of the adult human body 
accounting for ≈38% of the total body mass (Relaix and Zammit, 2012). This 
system is composed by approximately 640 different muscles (depending upon 
anatomical classification) and is responsible for: 1) movement and posture; 2) 
supporting soft tissues; 3) guarding body openings; 4) maintaining body 
temperature; 5) storing nutrients (Janssen et al., 2000). The functional units of 
a skeletal muscle are cylindrical structures named myofibres. A myofibre 
contains up to hundreds of nuclei sharing a continuous cytoplasm. These 
syncytial cells are formed by the fusion of mononuclear progenitor cells 
termed myoblasts (Mintz and Baker, 1967). While the length of a human 
myofibre can easily sit in the range of centimetres, its diameter is normally 
around 10-100µm (Ropper A., 2014). Each myofibre contains bundles of 
myofibrils, which are composed of a repeated series of thousands of 
sarcomeres.  Within each sarcomere are filaments of actin and myosin that 
interact to produce the force (Huxley, 1974). During postnatal growth the 
overall number of myofibres remains constant, but each myofibre grows in 
size by additional myoblast fusion (Yin et al., 2013). While the specific force of 
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a muscle fibre depends on its diameter, the strength of the whole muscle 
structure depends mainly on the combination of diameter and number of 
fibres composing it (Krivickas et al., 2011). The diameter of the fibres, the 
content of myoglobin, the presence of different myosin isoforms and the 
number of mitochondria determine the speed of contraction (Scott et al., 
2001).  
Muscle fibres are classified in two groups according to their speed of 
contraction: type 1, slow-twitch fibres characterised by an oxidative 
metabolism and type 2, fast-twitch fibres predominantly glycolytic. Type 2 
fibres can be sub-grouped in 2a, 2b and 2x on the basis of the myosin isoform 
composing their sarcomeres that in turn influence the speed of contraction 
(2b being the fastest). Virtually all muscles are composed of a mixture of type 
1 and 2 myofibres though in variable proportion (Scott et al., 2001). 
Figure 1. Structure of the skeletal muscle. The image depicts the structure 
of a skeletal muscle, and its anchoring to the bone through a stiff connective 
tissue structure named tendon. The arrows point to the hierarchy of 
connective tissue structures, that contributes to the stability of the tissue 
embedding the muscle fibres in bundles named fascicles. (Illustration 
obtained from the “Biotechnology learning hub” public repository). 
The myofibres run in parallel along the muscle’s axis while a layer of 
connective tissue named epimysium holds the whole structure together. 
Within the epimysium, myofibres are grouped in bundles (named fascicles) 
that are held together by an additional connective tissue layer named 
perimysium. This infiltrates between the myofibres, creating a thin scaffold 
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named the endomysium, which is also part of the basal lamina of the muscle 
fibres (Figure 1) (Light and Champion, 1984). This layered structure of 
connective tissue contributes to the stiffness and stability of the muscle tissue 
and creates the environment defined as the muscle stem cell niche (Yin et al., 
2013). The muscular blood supply relies on the presence of an arterial tree 
that branches through the epimysium, generating a large number of branches 
through the perimysial layer. A tight capillary network originating from these 
arterioles surround the single muscle fibres running along the endomysium. 
These capillaries need to adapt their length depending on the contracted or 
relaxed status of the muscle, and for that purpose they are characterised by a 
sinusoidal spring-like shape (Korthuis, 2011). Myoglobin, a protein present in 
the muscle, is smaller but similar to haemoglobin (its circulating counterpart) 
and guarantees oxygen supply to the tissue. Myoglobin and mitochondria are 
abundant in slow-twitching myofibres, allowing the continuous production of 
energy through an oxidative metabolism. For this reason muscles rich in slow 
fibers do not undergo fatigue. In contrast, fast-twitching muscles allow rapid 
movements but their metabolism is glycolytic and thus they fatigue after 
repetitive contractions (Kendrew et al., 1958; Nelson, 2000). 
1.1.2. Muscle contraction 
The mechanics behind skeletal muscle contraction have been outlined by a 
theoretical approach developed independently by Rolf Niedergerke, Jean 
Hanson, Hugh and Andrew Huxley in the early 1950’s and is commonly 
known as the sliding filament theory (Huxley and Niedergerke, 1954; Huxley 
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and Hanson, 1954). During the active phase of this process the sarcomeres 
shorten, generating what has been consequently defined as the contraction 
force. The contraction of a muscle relies on the simultaneous contraction of 
the single myofibres composing it. 
Figure 2. Schematic representation of the sarcomeric structure. The 
thick myosin filaments (green) are the active component of the contractile 
apparatus. The thin filaments are composed of actin (red), troponin (orange) 
and tropomyosin (yellow). Titins (light blue) anchor the thick filaments to the 
alpha-actinin composing the Z-disk (purple). Thanks to the presence of a 
central spring-like domain (blue), titins are responsible for the passive 
elasticity and stiffness of the muscle tissue. T tubules are invaginations of the 
sarcolemma and are depicted at the edges of this scheme (light blue). The T 
tubule network mediates the transduction of the action potential through an 
acetylcholine-receptor-mediated depolarization. This depolarization causes 
the release of calcium ions from the sarcoplasmic reticulum cisternae located 
between the T tubules and the Z disk, initiating the muscle contraction. 
Adapted from Kobirumaki-Shimozawa et al. (2012). 
An action potential originated in the central nervous system reaches the 
muscles through a motor neuron, which is responsible for transmitting the 
stimulus down its axon to the muscle. In resting conditions, vesicles 
containing acetylcholine are localised where the motor neuron comes in close 
proximity with the myofibre forming an area with a convolute pretzel-shape 
structure named neuromuscular junction (NMJ) (Balice-Gordon and Lichtman, 
1990; Sine, 2012). The action potential causes an influx of calcium ions 
towards specific voltage-gated channels present at the NMJ. This calcium 
influx causes the fusion of the acetylcholine-containing vesicles with the 
plasma membrane, leading to the release of its contents in the extracellular 
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space. For this reason, muscle contraction can be described as a calcium-
mediated process (Szent-Gyorgyi, 1975). Here the acetylcholine associates 
with the nicotinic acetylcholine receptor, a pentameric trans-membrane ion 
channel present on the myofibre membranes in areas concomitant with the 
neuromuscular junction (Miyazawa et al., 2003). This activation causes an 
immediate influx of sodium through a Na+ / K+ channel, triggering an action 
potential which is then propagated through the myofibre membrane towards a 
network of T-tubules (light blue in figure 2). T-tubules are normally located in 
between two sarcoplasmic reticulum structures named terminal cisternae, to 
form a cluster known as the triad. This depolarisation activates voltage-
dependent L-type calcium channels in the T tubule causing calcium release 
(via calcium releasing channels named ryanodine receptors) at each of its 
contact points with the sarcoplasmic reticulum. At this stage the sarcoplasmic 
reticulum releases calcium ions into the cytoplasm, which leads to the 
movement of troponin C and causes its conformational change and the 
dissociation of troponin from tropomyosin, a molecule composing the thin 
filaments (Figure 2). This conformational change exposes the myosin-binding 
domain of the actin filaments. Myosin is the engine of muscle contraction and 
the main component of the thick filaments (Figure 2). At this stage myosin, 
which has an ATPase domain, uses the energy obtained by hydrolysing it to 
ADP+P to bind to the actin filaments and pull them in a ‘power stoke’, 
generating the contraction. These movements cause a reduction in the 
distance between the Z-disks, shortening the sarcomere and consequently 
the whole muscle structure. This phenomenon has been for this reason 
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defined as ‘contraction’. This process, known as the sliding filament theory, is 
repeated as long as calcium is freely bound within the thin filaments and ATP 
is available. Relaxation occurs by a sequence of events including: 1) 
degradation of the acetylcholine operated by acetylcholinesterases, 2) 
termination of the action potentials; 3) sarcoplasmic reticulum stopping 
calcium release and starting to actively pumping it back within its 
compartments. A lack of calcium induces a conformational switch in the 
troponin / tropomyosin, which masks the myosin binding domain on the actin 
filaments, preventing the activity of myosin heads. At this stage, the elastic 
tension built on tendons leads to passive elongation of the muscle fibre that 
returns to its resting state. 
1.1.3. Muscle repair / regeneration 
Skeletal muscle fibres (also known as myofibres) are syncytial cells 
containing several hundreds of post-mitotic nuclei. Healthy muscles have 
large myofibres with peripheral myonuclei. Although skeletal muscle is a post-
mitotic tissue, it preserves the ability to regenerate following injuries, intense 
exercise or as a consequence of degenerating pathologies such as muscular 
dystrophies (Carlson, 1973; Tedesco et al., 2010). The process through which 
muscle regeneration occurs has been a controversial topic for a long time; 
specifically, whether regeneration occurs due to fusion of mono-nucleated 
precursors, or by generation of mono-nucleated cells derived from 
fragmentation of the damaged myofibres. Various papers published across 
1960 and 1961, provided compelling evidence that, at least in higher 
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vertebrates, myofibres originate and regenerate from fusion of mononuclear 
cells (Capers, 1960; Konigsberg, 1960; Pietsch, 1961; Stockdale and Holtzer, 
1961).  
Alexander Mauro reported the presence of mononuclear cells located 
beneath the ensheathing endomysial basal lamina that surrounds the 
myofibres. These mono-nucleated cells have their niche at the periphery of 
the myofibres on top of the sarcolemma and have been named satellite cells 
due to their anatomical position (Mauro, 1961) Satellite cells are considered 
the main players in post-natal skeletal muscle growth, tissue homeostasis and 
regeneration. Upon damage, these resident stem cells exit their quiescent 
status, undergo asymmetric cell division and generate transient amplifying 
progenitors named myoblasts, which expand upon symmetric cell division 
(Relaix and Zammit, 2012; Sambasivan and Tajbakhsh, 2015; Tedesco et al., 
2010; Yin et al., 2013). Mintz and Baker formally demonstrated that after an 
initial proliferative phase, myoblasts contribute to muscle regeneration by 
differentiating and undergoing cell fusion to repair the damaged myofibres or 
to replace them with newly formed ones (Mintz and Baker, 1967). Satellite cell 
activation has been shown to support muscle regeneration even after 
repeated muscle-wide / toxin-induced injuries, requiring the generation of a 
large number of myoblasts on each occurrence (Luz et al., 2002). A study 
from the 1960’s also demonstrated that this regeneration mechanism is so 
strong that is able to restore muscle function even if an entire muscle is 
explanted, minced and relocated back in situ (Studitsky, 1964). 
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The nuclei of mature healthy fibres are located at the periphery of the 
fibre, underneath the plasma membrane. Regenerating muscles, are 
characterised by fibre size heterogeneity, increased number of centrally 
nucleated myofibres and for the presence of an increased number of small 
regenerating fibres (identifiable by a reduced cross sectional area) (Maughan 
et al., 1983; Wroblewski et al., 1982). Skeletal muscle repair involves also the 
infiltration of inflammatory cells and fibroblasts contributing to the removal of 
the necrotic damaged fibres and to the tissue remodelling process 
(respectively). In patients with severe muscular dystrophies, the regeneration 
process fails as a consequence of the exhaustion/dysfunction of the stem cell 
pool. The infiltrate cells start depositing non-contractile extracellular matrix, 
collagen and fat in the interstitium in a process named fibrosis, interfering with 
the muscle function, strength and regeneration ability (Mann et al., 2011).  
 
 
Figure 3. Histological hallmarks of muscle degeneration, regeneration 
and fibrosis. The panel shows microphotography images of canine skeletal 
muscle sections. The top images (a) represent sections stained with 
haematoxylin and eosin. The canine DMD model depicted on the right shows 
the presence of centrally nucleated myofibres indicating active muscle 
regeneration. Notably, the diameter of the fibres is less homogeneous than 
the one of the control section on the left. The bottom part of the panel (b) 
shows a Masson trichrome staining performed on control (left) and dystrophic 
(right) samples. This staining highlights in red the myofibres while connective 
tissue infiltrate is stained in blue showing clear signs of fibrosis in the 
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dystrophic sample on the right (Scale bar 100 µm). Adapted from Smith et al. 
(2011). 
In addition to satellite cells and myoblasts, several other progenitors such as 
interstitial cells and pericytes have been shown to undergo myogenic 
differentiation during development, regeneration or upon transplantation 
(reviewed in (Benedetti et al., 2013; Peault et al., 2007; Tedesco et al., 2010). 
A specific section of this thesis details these cell types, focussing on their role 
and possible applications for cell therapy.  
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1.2. Muscle satellite cells and myoblasts 
Satellite cells were first observed via transmission electron microscopy by 
Alexander Mauro in 1961 and are located in a peripheral position to the 
muscle fibres. These cells have a high nucleus to cytoplasm ratio and their 
anatomical position is intimately juxtaposed to the muscle fibres, with their 
niche underneath the myofibre basal lamina (Mauro, 1961). As demonstrated 
with experiments performed in the early 1980’s, using developing chick and 
quails, satellite cells originate from the somites, spheres of paraxial 
mesoderm that generate skeletal muscle, axial skeleton and dermis (Armand 
et al., 1983; Gros et al., 2005; Sambasivan and Tajbakhsh, 2007). A 
pioneering study by Michael Rudniki and colleagues linked satellite cells to 
the paired box transcription factor Pax7, showing that inactivation of this gene 
led to a severe depletion of this cell population (Seale et al., 2000). Different 
lineage tracing experiments ascribed the origin of satellite cells to the 
appearance of Pax7 or Myf5 positive cells at different stages of embryonic 
development; however the exact progenitors that give rise to satellite cells still 
remain to be identified (Biressi et al., 2013; Lepper and Fan, 2010; 
Tajbakhsh, 2009; Zammit et al., 2004). Quiescent satellite cells represent 
around 6% of the total number of nuclei of a healthy adult muscle and can be 
identified by the expression of Pax7 (Zammit et al., 2006b) (Figure 4). Pax7 is 
indeed present virtually in all the quiescent satellite cells of the adult muscle 
(Gnocchi et al., 2009) and has been shown to have an essential role for their 
lineage specification and survival (Kuang et al., 2006).  
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Figure 4. Immunofluorescence for Pax7 on a single myofibre isolated 
from a murine skeletal muscle. The image depicts a freshly isolated single 
myofibre obtained from a wild type murine muscle. In the phase contrast 
image on the left (a), it is possible to appreciate the striped sarcomeric 
structure and the presence of a single cell at the periphery. The image on the 
right (b) shows an immunofluorescence staining of the same fibre for the 
satellite cell marker Pax7 (depicted in green). The peripheral cell stains 
positive for Pax7 and is therefore identified as a satellite cell. The myofibre 
was counterstained with Hoechst (blue) to visualise the nuclei (Scale bar 
15µm). 
Radioactive thymidine tracing experiments demonstrated that in the adult, 
satellite cells are mitotically quiescent but can undergo activation and rapidly 
enter the cell cycle following an injury (Snow, 1977). Satellite cell activation is 
a complex process that involves the combination of different signals coming 
from the damaged myofibres, but also from vasculature and innervation (Yin 
et al., 2013). Satellite cells undergo both symmetric and asymmetric cell 
division as shown in label retention experiments on purified cells (Rocheteau 
et al., 2012; Shinin et al., 2006). The whole regeneration process occurs in 
the mouse in approximately one week after toxin-induced damage during 
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which asymmetric and symmetric cell divisions are finely regulated to 
maintain the stem cell pool (Whalen et al., 1990; Zammit et al., 2002) 
The differentiation process is mainly controlled in vertebrates by four 
myogenic regulatory factors (MRFs): MyoD, Myf5, Mrf4 and Myogenin 
(Buckingham, 2001; Hammond et al., 2007; Pownall et al., 2002). Myf5 and 
MyoD mainly control the progression of activated satellite cells towards the 
myogenic differentiation (Tajbakhsh et al., 1996). Subsequently these 
activated cells start expressing Myogenin and start fusing to form 
regenerating fibres that finally also express MRF4 (Montarras et al., 1991).  
The status of a satellite cell can be defined according to its marker 
expression pattern. As shown in Figure 5, Pax7 positive / MyoD negative 
satellite cells can be defined as quiescent. Activated satellite cells, which 
undergo asymmetric and symmetric cell division, should be positive for both 
the markers (Pax7 positive / MyoD positive). However, MyoD positivity as 
defining criteria to identify activated satellite cells is still debated, suggesting a 
more relevant role for Myf5 (Kuang et al., 2008; Rudnicki et al., 2008). 
Myoblasts, canonically undergoing only symmetric expansion, progressively 
turn off Pax7 and activate Myogenin lately towards their transition to the 
“myocyte” status. These committed myocytes then differentiate fusing to form 
new myofibres and turn off MyoD (please refer to Figure 5 for a schematic 
overview on the process of satellite cell activation). 
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Figure 5. Satellite cell activation. The scheme depicts the process of 
satellite cell activation, which in vivo is followed by asymmetric cell division. 
Pax7, MyoD, and Myf5 are expressed in differentiating cells while only Pax7 
is expressed in the cells returning to quiescence in order to replenish the pool 
of progenitors. Adapted from Tedesco et al. (2010). 
The regenerative potential of satellite cell-derived myoblasts was confirmed in 
the early nineties, with experiments showing that transplanted myoblasts can 
sustain host muscle regeneration upon serial injury (Morgan et al., 1993; Yao 
and Kurachi, 1993). The first formal evidence of quiescent satellite cell self-
renewal was obtained with single fibre transplantations into regeneration-
insufficient irradiated mice. This experiment demonstrated that as few as 
seven satellite cells can give rise to thousands of myonuclei and hundreds of 
satellite cells able to support subsequent rounds of muscle regeneration 
(Collins et al., 2005). The self-renewal potential of satellite cells was then 
confirmed with a lineage tracing experiment in which Pax7 / nGFP positive, 
freshly isolated satellite cells sustained up to 7 rounds of serial 
transplantation, contributing to muscle regeneration and to the maintenance 
of a pool of Pax7 / nGFP positive satellite cells (Rocheteau et al., 2012). 
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1.3. Pericytes and mesoangioblasts 
Although firstly observed by Eberth in 1871 (Eberth, 1871), paternity of the 
pericyte identification is generally assigned to Rouget. The French scientist 
described these as a population of contractile cells which surrounds the blood 
vessel walls (Rouget, 1874, 1879). Rouget cells have since been re-named 
pericytes, referring to their anatomical localisation in close immediacy to the 
endothelial layer (Zimmermann, 1923). In the first half of the twentieth 
century, numerous publications described pericytes, questioning also their 
ability to contract. This partly reflects pericyte heterogeneity and the confusion 
about their cell identity (Armulik et al., 2011). Currently cells defined as 
pericytes are localised in the vascular basal membrane as seen via electron 
microscopy (Miller and Sims, 1986). These cells possess a prominent 
nucleus, a small content of cytoplasm and several large cytoplasmic 
protrusions. Nowadays, it is clear that different cell types are located in the 
perivascular compartment and the correct identification of the various sub-
populations is still challenging (Krueger and Bechmann, 2010). The clear 
identification of these cells becomes even more difficult in conditions of active 
angiogenesis such as during embryogenesis and tissue regeneration. It is 
also widely accepted that pericytes are more frequent in the proximity of 
micro-vessels (capillaries, venules and terminal arterioles), although this has 
been recently challenged by the observations of sub-endothelial pericyte-like 
cells in large vessels (Diaz-Flores et al., 2009). Vascular smooth muscle cells 
(VSMCs), fibroblasts, and macrophages recurrently occupy the 
periendothelial position together with pericytes (Armulik et al., 2011). The 
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view that pericytes and vascular smooth muscle cells belong to the same 
lineage is commonly accepted. However, it is important to consider that no 
single molecular marker has been recognised as unequivocally identifying 
pericytes and distinguishing them from vascular smooth muscle cells 
(VSMCs) and other perivascular mesenchymal cells. The multiple markers 
generally utilised, are neither cell-specific nor constant in their expression 
(Armulik et al., 2011). Perivascular cells have been classified as pericytes 
(peri, around; cyte, cell) or alternatively as vascular mural cells or vascular 
smooth muscle cells (VSMC) depending on their morphology and location 
(Hirschi and D'Amore, 1996; Zimmermann, 1923). These cells are located 
around blood capillaries, arterioles and venules. In these vessels, endothelial 
cells and pericytes share the basal membrane and are connected by tight, 
gap, and adherens junctions. A single pericyte can be indeed connected with 
several endothelial cells by cell protrusions that wrap around and along the 
blood vessel (Gerhardt and Betsholtz, 2003; Kovacic and Boehm, 2009). 
Pericytes detected around large arteries not only occupy the periendothelial 
position, but can be found in the media and adventitia associated with the 
vasa vasorum (Andreeva et al., 1998). Distinguishing between pericytes and 
VSMC is a complicate; moreover it is not possible to exclude that one cell 
type may represent subtypes of the other or that these share the same 
progenitors. It has also been suggested that pericytes that reside in close 
proximity with the endothelium of large vessels could be the progenitors of 
VSMC (Armulik et al., 2005; Armulik et al., 2011). Pericytes number and 
distribution is highly variable according to size and vessel type. These cells 
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are frequently found on small venules and arterioles and more rarely on 
capillaries; they cover irregularly the veins with large membrane processes 
while they continuously cover the arteries where they form an embedding cell 
layer. Blood pressure has been indicated as one of the factors regulating their 
distribution, as observed in the retina (Wallow et al., 1993). The heterogeneity 
of pericytes is shown in the differences observed in correlation to the organ in 
which they are located. In the central nervous system, they interact via tight 
junction with the endothelial cells, composing the blood brain barrier (BBB) 
(Ballabh et al., 2004). Kidney pericytes are also known as mesangial cells 
(Betsholtz et al., 2004), while in the liver they are named Ito cells (Ito and 
Nemoto, 1952). In the murine and human skeletal muscle, 90% of the 
capillaries have been found to be associated with Neuro-glial 2 proteoglycan 
(NG2) positive pericytes (Kostallari et al., 2015). 
 
Figure 6. Schematic representation of pericyte location and functions. 
The scheme depicts the most commonly recognised functions in which 
pericytes (in green in the scheme) have a crucial role (Winkler et al., 2011a). 
Pericytes have several functions in all tissues. In the central nervous system 
for example, pericytes are one of the main components of the blood-brain 
barrier (BBB) and together with vascular smooth muscle cells, have been 
indicated as potentially responsible for blood flow regulation through 
vasoconstriction / dilation mechanisms (Rucker et al., 2000) (Figure 6). They 
do this by directly interacting with the extracellular matrix and closely with 
endothelial cells via gap junctions (Li et al., 2011). Another process in which 
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pericytes have a crucial role is angiogenesis. This process requires both the 
recruitment of endothelial cells from pre-existing vessels (Lamalice et al., 
2007) and of pericytes from the surrounding tissue (Armulik et al., 2005) via 
different signalling pathways such as delta-mediated Notch signalling, PDGF 
and TGF-β that will be further detailed in the next paragraphs of this thesis. 
Because of all these different characteristics and locations, it is 
particularly difficult to concur on a universal definition of pericytes. Some 
cytoskeletal proteins such as Desmin, a muscle specific class III intermediate 
filament protein, and α-smooth muscle actin (SMA) have been used to identify 
pericytes. Desmin is, for example, normally also expressed by differentiated 
skeletal, cardiac and smooth muscle cells; whereas SMA is also known to be 
present on smooth muscle cells and myofibroblasts (Nehls et al., 1992; 
Ronnov-Jessen and Petersen, 1996). NG2 is a chondroitin sulphate 
proteoglycan strongly expressed by pericytes, in particular during 
angiogenesis and can bind basic-FGF, PDGF-AA, plasminogen and 
angiostatin (Abboud, 1995). Therefore NG2 has been commonly utilised to 
identify pericytes. NG2 knockout mice are viable, but show compromised 
revascularisation upon damage (Ozerdem and Stallcup, 2004; Rajantie et al., 
2004). However, this proteoglycan is not specific for pericytes and is 
commonly expressed by other cell types such as immature neural stem cells 
capable of differentiation into neurons or glia. PDGFr-β (Platelet-Derived 
Growth Factor Receptor beta) is also a commonly utilised pericyte marker. 
This receptor is localised in the pericyte membrane and has a crucial role in 
the recruitment of these cells by the endothelium during angiogenesis 
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(Betsholtz, 2004). PDGFr-β deficient mouse embryos lack micro-vascular 
pericytes and develop frequent micro-aneurysms (Lindahl et al., 1997). 
Analysis of the gene expression profile of these PDGFr-β deficient mice 
highlighted the lack of RGS-5 (a regulatory G protein); for this reason RGS-5 
has been recently proposed as a novel pericyte marker (Berger et al., 2005). 
CD13 is a surface marker that was utilised to identify pericytes in the early 
nineties (Kunz et al., 1994), is now less common because the expression of 
this protein is also observed in vascular smooth muscle cells, inflamed 
endothelium, myeloid, epithelial and gut cells (Armulik et al., 2011).  
Alkaline phosphatases (APs) are a group of glycoproteins able to 
hydrolyse a large range of monophosphate esters and have their optima at an 
alkaline PH. The first evidence linking AP expression to the capillaries, was 
published in 1965 (Mizutani and Barrnett, 1965). In humans, four AP isoforms 
have been recognised while there are only three in the mouse (Stefkova et 
al., 2015). Although its physiological function is still unknown, AP is 
histochemically traceable in the mouse embryo as early as the 2-4 cell stage 
(Mulnard and Puissant, 1987). The tissue nonspecific isoform (TnAP) is 
conserved across the species and its sequence (composed of 12 exons) 
codes for an enzyme expressed by a subset of pericytes of the skeletal 
muscle (Grim and Carlson, 1990; Safadi et al., 1991) bone and heart 
(Schultz-Hector et al., 1993).  AP-positive cells have been easily isolated from 
skeletal muscle and cultured in vitro, showing mesenchymal morphology and 
pericyte marker expression (Levy et al., 2001).  
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Figure 7. Pericytes and mesoangioblasts. The diagram depicts 
mesoangioblasts (in vitro counterpart of the AP+ pericytes), as a subset of 
muscle pericytes, subgroup of the general ensemble of vessel associated 
pericytes. 
A pioneering study published in 2002, in collaboration between the groups of 
Paolo Bianco and Giulio Cossu, reported that cells isolated from the 
embryonic murine dorsal aorta and ascribed to the perivascular lineage (by 
the expression of CD34, Flk-1, SMA and c-Kit), were able to generate in vivo 
different mesodermal tissues. For this reason, these cells have been named 
mesoangioblasts (Minasi et al., 2002). Similar cells have been subsequently 
isolated from murine (Sampaolesi et al., 2003), canine (Sampaolesi et al., 
2006) and human skeletal muscle biopsies (Dellavalle et al., 2007) and 
resulted capable to contribute to skeletal muscle regeneration also upon intra-
arterial delivery. Adult mesoangioblasts are defined as the in vitro counterpart 
of a subset of muscle pericytes expressing Alkaline Phosphatase (Figure 7). 
Taken together, these properties make mesoangioblasts an appealing 
	 37	
candidate for cell therapy purposes (Sampaolesi et al., 2005). Interestingly, 
recent lineage tracing experiments have shown that TnAP-positive pericytes 
and their progeny, contribute to postnatal muscle development and give rise 
to Pax7 positive satellite cells during growth and regeneration (Dellavalle et 
al., 2011).  	  
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1.4. The muscular dystrophies  	
Muscular dystrophies are a heterogeneous group of inheritable myopathies 
involving muscle tissue degeneration, with considerable variation in their 
clinical manifestation and severity (Emery, 2002). Overall, these pathologies 
are characterised by a progressive weakening and degeneration of the 
skeletal muscle tissue (Mercuri and Muntoni, 2013). The unifying feature of 
these pathologies is regarded as the altered muscle morphology. Histological 
studies have shown variations in fibre size, monocyte infiltration, necrosis and 
replacement by fat and connective tissue (Emery, 2002). These pathologies 
have been grouped in different categories in accordance with the 
predominant distribution of the main symptom, the muscle weakness (Figure 
8). In some forms of muscular dystrophy a cardiac involvement is present with 
variable extent (Verhaert et al., 2011). Variable cognitive impairment has 
been also reported in some forms of muscular dystrophy such as in DMD 
(Bresolin et al., 1994; Wicksell et al., 2004), dystroglycanopathies (Waite et 
al., 2012), and in  some forms of congenital muscular dystrophy (Cardamone 
et al., 2008). Different hypostesis have been formulated to explain the 
cognitive impairment observed in DMD. Clinical investigation of the role of 
dystrophin in the central nervous system suggested that its lack might have 
significant relevance in explaining this defect. Interestingly, a recent report 
highlighted that a three base-pair deletion affecting the brain isoform of 
dystrophin’s binding site for the β-dystroglycan is sufficient to cause 
intellectual disabilitiy either in patients that shows no muscular symptoms (de 
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Brouwer et al., 2014). It has been postuated that lack of dystrophin correlates 
with alterations in the distribution and function of the GABAA inhibitory 
receptor impacting on the clinical efficacy of drugs, sleep disorders and motor 
control. These phenomena are frequently alterated in DMD patients 
(Anderson et al., 2002). Defects in the assembling and processing of the 
distroglycan complex in both neurons and glia are also associated with a 
spectrum of brain abnormalities. The role of dystrophin and the dystroglycan 
complex in the clustering of GABAA receptors may explain the association of 
DMD mutations with cognitive impairment in some patients (Waite et al., 
2012).  
 
Figure 8. Distribution of predominant muscle weakness in different 
types of muscular dystrophy. A, Duchenne-type and Becker; B, Emery-
Dreifuss; C,limb-girdle; D, facioscapulohumeral; E, distal, F, oculopharyngeal. 
The affected areas are shaded in grey (Emery, 2002).  
Although some forms of muscular dystrophy affect nuclear membrane 
proteins, the majority of these pathologies involve, directly or indirectly, genes 
coding for components of the dystrophin associated protein complex (DAPC) 
(Figure 9), located on the myofibre membrane (Ervasti et al., 1990). This 
complex functions as a link between the intracellular F-actin cytoskeleton and 
the extracellular matrix (Davies and Nowak, 2006). Overall, this group of 
genetic defects causes alterations in the mechano-elastic support to the 
muscle contraction, leading to ruptures of the myofibre membrane. 
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Figure 9. Schematic representation of the Dystrophin associated protein 
complex (DAPC). The scheme depicts the main components of the DAPC. 
Dystrophin is located inside the cell and its N-terminus is bound to the actin 
cytoskeleton. The C-terminus is associated to a large complex of membrane 
glycoproteins. This consists of sarcoglycans (α, β, γ, and δ subunits), 
dystroglycans (α - and β ), sarcospan, and syntrophins (α - and β ). 
Mutations in the dystrophin gene lead to BMD and DMD. Mutations in the 
sarcoglycan subunits cause various forms of limb girdle muscular dystrophy 
(LGMD). LGMD2B is caused instead, by mutation in the gene coding for 
Dysferlin. LGMD2I is a distinct form of LGMD caused by a mutation in the 
FKRP gene, encoding a Golgi apparatus protein. Mutations in the genes 
encoding the nuclear envelope protein emerin and lamin A/C cause Emery-
Dreifuss muscular dystrophy and various forms of Laminopathy. 
Abbreviations: bm, basement membrane (basal lamina); pm, plasma 
membrane (plasmalemma); NMJ, neuromuscular junction; AChR , 
acetylcholine receptor. Adapted from Emery 2002. 
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More than half of the identified forms of muscular dystrophy are grouped 
under the definition of limb-girdle muscular dystrophies (LGMD); other forms 
include Emery-Dreifuss, distal, facioscapulohumeral (FSHD) and 
oculopharingeal muscular dystrophy (OPMD), congenital muscular dystrophy 
(CMD). Auspiciously, the genetic defects causing the most common of these 
disorders have been already identified. This essential information allows 
accurate diagnosis making also feasible genetic counselling and prenatal 
screenings (Emery, 2002). 
As mentioned above, some of these pathologies directly affect proteins 
composing the DAPC; this includes for example Duchenne muscular 
dystrophy (detailed in the next paragraph) and sarcoglycanopathies (forms of 
limb girdle muscular dystrophies involving the sarcoglycans) (Gordon and 
Hoffman, 2001). In some forms of LGMD and CMD the DAPC is indirectly 
affected. In dystroglycanopathies for example, mutations are mainly affecting 
genes like FKTN, FKRP, POMT1, POMT2 and POMGNT1, ISPD and LARGE 
causing a defect in the post-translational glycosylation of α-Dystroglycan. 
Dystroglycans are responsible of forming a link between the actin 
cytoskeleton and the extracellular matrix and alteration in its glycosylation 
status interfere with this interaction causing a broad spectrum of muscle and 
non muscle-related symptoms (Muntoni et al., 2011). Laminopathies are a 
heterogeneous group of diseases affecting the LMNA gene and its splicing 
products lamin A and C. These proteins, together with emerin are major 
components of the nuclear lamina and play a fundamental role in the 
organization of the nuclear architecture in all human cells. Laminopathies 
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cannot be defined as muscle disorders sensu stricto. Not all mutations in the 
LMNA gene results in a muscle disease phenotype. However, some forms of 
these diseases manifest predominantly with muscle weakness and 
degeneration, as in the case of LMNA-related congenital muscular dystrophy 
and Emery-Dreifuss muscular dystrophy. Notably in these pathologies, the 
DAPC is not involved at all (Bione et al., 1994; Brown et al., 2008; Mercuri et 
al., 2004; Scharner et al., 2010). 
Dystrophic muscles are subjected to continuous degeneration and 
regeneration cycles. This dysfunction is initially compensated by the resident 
tissue progenitors that increase their number of symmetric and asymmetric 
divisions to regenerate the damaged tissue, leading to an initial phase of 
muscle pseudo-hypertrophy (Reimers et al., 1996). However, this 
compensatory mechanism is not sufficient to sustain long-term tissue 
regeneration, mainly because the newly formed muscle / myofibres carry the 
same genetic defects, resulting in the same level of fragility and subsequent 
degeneration.  Additionally, this increased number of cell divisions causes the 
premature exhaustion of the resident muscle stem cell pool (Sacco et al., 
2010). As mentioned above, the repeated cycles of degeneration-
regeneration that the muscle tissue undergoes, with the constant presence of 
necrotic and damaged myofibres, result in a chronic inflammatory status, 
reflected by an increased resident monocyte presence, combined with fibrotic 
and adipose infiltration. Indeed, dystrophic patients in an advanced stage of 
the disease show extensive muscle fibrosis, where the myofibres are 
replaced with fat and connective non-contractile tissue, causing a permanent 
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loss of muscular function (Mann et al., 2011). This might be even worsened 
by transient aberrant vascular regulation observed in some DMD patients 
(Palmieri et al., 1988). Studies on transgenic mice ascribed this phenomenon 
to the lack of dystrophin in the vascular smooth muscle, causing the 
anomalous NO-dependent modulation of α-adrenergic vasoconstriction in the 
active muscles, leading to transient ischaemic events and contributing to 
patient’s muscle degeneration (Ito et al., 2006; Thomas, 2013).  
The lifespan and quality-of-life of the patients affected by muscular 
dystrophies has significantly improved in the last two decades, mainly thanks 
to advanced corticosteroid treatment regimes and improvements in the 
standards of care (Bushby et al., 2010a, b). It is important to mention that 
currently there is no definitive treatment that can affect the long-term 
progression of this group of diseases. Advancements in pharmacological 
approaches, gene manipulation and stem cell therapies are suggesting 
cautious optimism on the possibility of finding definitive cures for certain / 
specific muscular dystrophies in the not-too-distant-future (Emery, 2002).  
1.4.1. Duchenne muscular dystrophy 
The most common of these pathologies, with an incidence of up to 1:3,500 
male children, is Duchenne muscular dystrophy (DMD; weakness distribution 
represented in Figure 8 A). The paternity on the identification of this pathology 
is still debated. Recent bibliographic research linked the discovery to an 
Italian physician named Gaetano Conte, who described two cases in a 
national scientific journal in 1836 (Nigro, 2010). The first international 
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publication describing this pathology appeared in 1851, authored by a British 
doctor named Edward Meryon (Emery, 2000; Meyron, 1851). This study 
highlighted the familial inheritance of the disease and that the vast majority of 
the patients affected were male. As a cause, Meryon, with an astonishing 
visionary intuition (given the then available methodology), excluded alteration 
in the spinal cord but linked the symptoms to rupture and destruction of the 
muscle membrane. Detailed histological analyses have since confirmed the 
fragility of the myofibres membranes and the presence of connective and 
adipose tissue infiltrate in the muscles of patient at the late stage of the 
disease (Meyron, 1851). This pathology owes its name to the French 
neurologist Duchenne de Boulogne, who detailed the clinical symptoms a few 
years later (Duchenne, 1868).  
DMD has an early onset in childhood, with the child experiencing 
difficulties running and climbing stairs. In this disease the muscle weakness is 
mainly proximal and progressive with most of the affected individuals 
becoming wheelchair-bound by the age of 12-15. The premature death of 
individuals in late adolescence mainly occurs because of cardiac and 
respiratory complications. Better clinical care of these conditions has 
significantly prolonged life expectancy and delayed progressive 
immobilisation, but patients are still facing a long final period of almost 
complete inability to move. 
It was only in 1987 that the DMD gene was identified as the defective 
molecule in DMD and its milder form, Becker muscular dystrophy (BMD) 
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(Hoffman et al., 1987). This gene is located in the Xp21 locus of the X 
chromosome. It is the largest gene known in nature (2.4Mb) and codes for a 
protein named dystrophin.  Dystrophin is usually absent in DMD patients (as 
shown in the figure 10), whereas it can be present in a reduced amount or 
abnormal size in patients with BMD. The dystrophin protein is one of the main 
components of the dystrophin-associated protein complex (DAPC) and is 
required for the stability of the complex (Petrof et al., 1993). When absent, the 
structural link between the cytoskeleton and the plasmalemma becomes 
fragile. Upon contraction, this weakens causing ruptures and damages to the 
myofibres. 
Clinical diagnosis is validated via immunohistochemistry and 
immunoblotting; further molecular analyses of the specific mutation revealed 
that most of the mutations causing DMD (60%) are intragenic deletions 
(Koenig et al., 1989). BMD is less frequent and less severe than DMD, 
although the gene and muscles affected coincide (Becker and Kiener, 1955). 
In BMD patients the production of dystrophin is not completely ablated, or the 
protein is present in a shorter isoform, thanks to spontaneous exon skipping 
events that exclude the exon containing the mutation at the transcriptional 
level. For this reason, progression and chronic muscular degeneration is 
generally slower in BMD patients, with a life expectancy that increases up to 
more than 50 years of age (Emery, 2002). 
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Figure 10. Immunofluorescence staining for Dystrophin on a healthy 
donor and DMD patient muscle cryo-section. The image shows an 
immunofluorescence staining performed using an anti-dystrophin monoclonal 
antibody. Healthy donor muscle biopsies show sharp dystrophin-positive rims 
at the periphery of the myofibres; this rim is generally absent in sections 
obtained from DMD patient biopsies. Adapted from Emery (2002) 
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1.5. Therapeutic approaches to treat muscular dystrophies 
 
Although no definitive cure for muscular dystrophies is available to date, a 
number of different experimental strategies aiming to treat dystrophic patients 
are currently under preclinical and clinical investigation. These strategies can 
be classified in three main different groups:	
- Pharmacological approaches 
- Exon skipping, gene editing and gene addition / replacement 
- Stem / progenitor cell therapies 
Each therapeutic approach aiming to treat dystrophic patients needs to face 
major challenges related to the nature of the disease itself. The need to target 
different muscles in the body, the cardiac and respiratory involvement (for 
DMD), the potential immune response (Maffioletti et al., 2014), the 
requirement of a long-term effect and the need to prevent or at least limit 
fibrotic tissue accumulation within the muscle all have to be taken into 
account (Mercuri and Muntoni, 2013; Tedesco and Cossu, 2012). The 
following paragraphs will give an overview on the mechanisms and results 
achieved with pharmacological and genetic correction strategies. A more 
comprehensive review on the cell therapy strategies adopted along the years 
will be provided.  In the cell therapy section, additional information will be 
given on the physiological role of the stem cells and progenitors relevant for 
this work: satellite cells and pericytes.  
1.5.1. Pharmacological approaches 	
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Different pharmacological approaches have been attempted to directly 
address the primary defect in muscular dystrophies, or in alternative to 
provide a functional compensatory system. Gentamicin and Ataluren (known 
also as PTC124) have been shown to restore the dystrophin expression in 
both in vitro and in vivo studies by suppressing nonsense mutations that 
frequently occur in Duchenne patients (Barton-Davis et al., 1999; Welch et al., 
2007). The mechanism underlying this strategy is the induction of a ribosomal 
read-through of the premature stop mutations, leading to the restored 
production of the full-length functional dystrophin. Despite a favourable 
pharmacodynamic response to the drug, recent clinical trials on Gentamicin 
have demonstrated modest beneficial effects accompanied by significant side 
effects (Malik et al., 2010). To reduce the toxicity of Gentamicin and increase 
its specificity, a hybrid liposomes-based drug-delivery system has been 
recently developed and might lead to a future clinical assessment (Yukihara 
et al., 2011). However encouraging results have been observed in a Phase II 
clinical trial with Ataluren, where it has been shown that this drug is beneficial 
at a relatively low dose, allowing its use in an on-going Phase III clinical trial 
where the long-term safety and efficacy will be assessed (Bushby et al., 
2014). Most importantly, in May 2014 the European Medicines Agency 
granted conditional marketing authorisation for this drug, under the 
commercial name of Translarna™, making it the first drug approved for the 
treatment of DMD patients (Ryan, 2014). 
An alternative pharmacological approach for DMD proposed in the 
early 1990’s by the group of Kay Davis consists in a functional compensation 
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of the missing dystrophin protein up-regulating its autosomal paralogue: 
utrophin (Tinsley and Davies, 1993). Increased levels of utrophin, achieved 
upon the overexpression of a truncated version of the transgene, can restore 
the assembly of the dystrophin associated protein complex (DAPC) at the 
level of the sarcolemma and have been shown to alleviate the dystrophic 
pathology in pre-clinical studies on animal models of DMD (Tinsley et al., 
1996). More recently, small molecule drugs have been shown to stimulate 
utrophin transcription. (Tinsley et al., 2011). Utrophin-based therapies have 
different advantages over the dystrophin-based ones. Being utrophin natively 
present in DMD patients, no immunological response is expected upon its up-
regulation at variance with what previously observed upon the introduction of 
a functional dystrophin (Mendell et al., 2010a; Wells et al., 2002). Utrophin-
based approaches might also be effective for all DMD patients, regardless of 
gene defect. Moreover, the use of small molecules open possibilities for 
systemic administration to the patients, since constitutive overexpression of 
utrophin in mdx mice resulted to be nontoxic (Fisher et al., 2001). These 
utrophin modulators have been recently tested in a Phase I clinical trial to 
investigate safety, tolerability and pharmacokinetics, with encouraging results 
(Tinsley et al., 2015).  
Several other drugs have been proposed with the aim of treating dystrophic 
patients and are undergoing preclinical and clinical experimentation. 
Examples include anti-inflammatory molecules (Serra et al., 2012), nitric 
oxide (Brunelli et al., 2007), IGF1 (Barton et al., 2002), agents capable of 
neutralising / blocking Myostatin (Wagner et al., 2008) and  more recently, 
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drugs to improve blood supply and muscle tissue oxygenation such as the 
PDE5 inhibitor Sildenafil, aiming to reduce the intrinsic muscle ischemia 
(Nelson et al., 2014). 
 
1.5.2. Exon skipping, gene editing and gene addition / 
replacement 
In order to induce de novo protein expression in patients affected by muscular 
dystrophies, exon skipping, gene correction and gene replacement therapies 
have been developed to: modulate the RNA processing; repair the underlying 
genetic defect or to replace the defective gene. 
1.5.2.1. Exon skipping 
In exon-skipping synthetic antisense oligonucleotides (AONs) hybridise 
specific pre-mRNA targeted motif, causing the “skipping” of the mutation-
containing exon. This process restores the normal mRNA reading frame 
leading to the production of a (slightly shorter) functional dystrophin protein, 
similar to what is found in BMD patients (Helderman-van den Enden et al., 
2010). Based on successful results obtained in preclinical in vivo studies (Lu 
et al., 2005; Yokota et al., 2009), exon-skipping technology has progressed to 
two main clinical trials: a phase III study of the oligonucleotide PRO051 
(Drisapersen) by Prosensa and GSK, and a phase IIb study of the 
oligonucleotide AVI-4658 (Eteplirsen) by Sarepta Therapeutics (Aartsma-Rus, 
2010; Mendell et al., 2013). Encouraging results were obtained in the phase II 
clinical trial on Drisapersen, indicating a slight increase in dystrophin 
production and better performance in the six minutes walk test (6MWT) 
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(functional assay commonly utilised to evaluate the muscle function in 
dystrophic patients) (Voit et al., 2014). However the phase III clinical trial on 
this drug has been prematurely interrupted by GSK since it failed to meet the 
primary endpoint of a statistically significant improvement in the 6MWT, 
where a possible reason has been ascribed to the relatively rapid clearance 
of the compounds from the circulation. Moreover, controversial interpretation 
of the results coming from these studies (i.e. the non-correlation of amount of 
dystrophin positive fibres via immunohistochemistry and the level of protein 
detected via western blot), revealed the need to refine those analytical 
approaches (Lu et al., 2014). In order to avoid repeated administration of 
AONs and enable sustained levels of dystrophin protein for a long-term 
therapeutic efficacy, modified small nuclear RNAs (U1 and U7snRNA) have 
been designed to shuttle AONs via recombinant adeno-associated vectors 
(rAAV) (Benchaouir and Goyenvalle, 2012). In this way, AONs involved in the 
repairing of the mutated genes (and the consequent restoration of gene 
expression), are efficiently delivered in vivo through viral vectors by 
enhancing the efficiency in comparison with their original way of being 
delivered. The potential of this approach has been shown in preclinical 
studies in murine and canine DMD models, where a single systemically 
delivered dose of rAAV-snRNA–mediated exon skipping was able to restore 
near-normal levels of dystrophin improving function in the muscles examined, 
including the heart (Denti et al., 2008; Goyenvalle et al., 2012; Vulin et al., 
2012).  
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Apart from DMD, the therapeutic potential of exon-skipping techniques 
has also been exploited for other muscular dystrophies, such as in vitro and in 
vivo studies conducted for myotonic dystrophy type 1 (Francois et al., 2011; 
Wheeler et al., 2012), limb-girdle muscular dystrophy 2B (Kergourlay et al., 
2014; Wein et al., 2010) and congenital muscular dystrophy (Aoki et al., 2013; 
Taniguchi-Ikeda et al., 2011).  
1.5.2.2. Gene editing 
Alternative gene correction strategies are based on the use of engineered 
nucleases for site-specific correction of mutated genes. Zinc-finger (ZFNs), 
transcription-activator like effector nucleases (TALENs), clustered regularly 
interspaced short palindromic repeats (CRISPR) and mega nucleases have 
been recently exploited to genetically correct pluripotent stem cells and 
myogenic progenitors (Bertoni, 2014; Rousseau et al., 2011). Meganucleases 
have been successfully used to correct a specific mutation in the dystrophin 
gene, leading to the restoration of the reading frame and to the expression of 
a truncated form of the missing protein in myoblasts in vitro and in vivo 
(Chapdelaine et al., 2010). In another study, meganucleases have been used 
to target a specific deletion in the DMD gene of human patient myoblasts 
resulting in expression of a full-length dystrophin (Popplewell et al., 2013). 
Other endonucleases, more efficient than meganucleases, have been taken 
into consideration for gene therapy approaches for muscular dystrophies. 
Ousterout and colleagues used both ZFNs and TALENs to exclude the 
mutated exon 51 of the dystrophin gene in DMD myoblasts leading to the 
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production of the protein both in vitro and upon transplantation in 
immunodeficient animals (Ousterout et al., 2015b; Ousterout et al., 2013).  
TALENs are also capable of highly efficient manipulation in pluripotent stem 
cells, and are characterised by low toxicity (Hockemeyer et al., 2011). This 
genome editing system has been recently used to correct the mutation and 
revert the phenotype in neural stem cells derived from a myotonic dystrophy 
type 1 (DM1) patient induced pluripotent stem cells (iPSCs) (Xia et al., 2015). 
Li and colleagues utilised recently a TALEN / CRISPR-based gene editing 
approach to genetically correct DMD iPSCs restoring dystrophin expression 
upon myogenic differentiation (Li et al., 2015). However, this approach can 
correct only one specific mutation and would require a specific design for the 
vast majority of patients. To overcome this limitation, a multiplex CRISPR / 
Cas9-based system has been developed to target the mutational hotspot at 
exons 45-55 of DMD gene in patient myoblasts, offering a system that can 
correct up to 62% of the known DMD mutations. The efficiency of this method 
was proven by the restoration of dystrophin expression in vitro and in vivo 
upon transplantation of the genetically corrected cells in immunodeficient 
mice (Ousterout et al., 2015a). These results can be considered the first steps 
towards novel gene editing-based therapeutic approaches. However, 
extensive in vivo studies on functional correction of the dystrophic phenotype 
still need to be performed. 
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1.5.2.3. Gene replacement 
Recent gene replacement approaches have successfully shown the 
possibility of providing an additional functional copy of the genes affected by 
the mutation causing the specific muscular dystrophy. These strategies aim to 
restore the production of the missing protein in order to recover the muscle 
function. Gene replacement methods do not face the mutation-specific 
limitations of the gene correction methods mentioned above, although safety 
and long-term efficiency of the gene delivery techniques are more challenging. 
Triggering an immune response against either the vector or the newly 
expressed protein is the main hurdle related to gene replacement methods. 
Moreover, the abundant volume of muscle tissue that needs to be treated in 
muscular dystrophies and its intrinsic feature of being composed of fibres 
surrounded by connective tissue affects the efficiency of delivering the gene 
of interest.  
The types of vectors currently under investigation to treat skeletal 
muscles can be divided into viral and non-viral. Viral vectors have been 
largely exploited as gene transfer vehicle for in vivo and ex vivo gene therapy 
approaches for muscular dystrophies, due to their ability to transfect different 
cell types and stably integrate into the genome. For example, helper-
dependent adenoviral vectors can accommodate the full-length dystrophin 
cDNA (14 kilobases) resulting in its efficient expression (Guse et al., 2012; 
Kawano et al., 2008), but the applicability of these vectors for a gene therapy 
purpose is limited by the need of multiple intramuscular administrations and 
	 55	
the high risk of immune response, highlighted in preclinical studies in non-
human primates (Brunetti-Pierri et al., 2004).  
Recombinant adeno associated virus (rAAV) vectors overcome some 
of these limitations and are suitable for systemic delivery (Gregorevic et al., 
2004; Lai et al., 2005; Wang et al., 2005) also exhibiting lower 
immunogenicity (Zaiss et al., 2002). For these reasons rAAVs are currently 
considered an ideal delivery tool for gene therapy for muscular dystrophies. 
However, this promising therapeutic approach is challenged by the small 
packaging capacity of these vectors (~ 4.5 kilobases), restricting their use to 
the delivery of small therapeutic genes such as the sarcoglycans or shorter 
versions of the dystrophin (Fougerousse et al., 2007; Gregorevic et al., 2006; 
Koppanati et al., 2010; Krahn et al., 2010). These encouraging results 
validated the use of rAAV vectors in large dystrophic animal models as well 
as in patients (Koo et al., 2011; Mendell et al., 2010b; Rodino-Klapac et al., 
2010; Wang et al., 2012). While rAAV resulted non immunogenic in mice, 
several studies have observed that rAAVs can elicit an immune response in 
a canine DMD model (Wang et al., 2007) and in humans (Mingozzi et al., 
2009) leading to a re-evaluation of the role of these viral vectors for future 
trials. Micro / mini-dystrophin have been engineered to fit the small rAAV 
cargo size. However it has been reported in both dogs and DMD patients, 
that T lymphocytes against these transgenes appear likely hampering their 
long-term expression (Mendell et al., 2010a; Yuasa et al., 2007). This 
indicates that further studies will be needed to develop systemic treatments 
for patients who suffer from muscular disorders (Nayak and Herzog, 2010) 
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Differently from rAAV, lentiviral vectors have a relatively large size 
capability (~ 7.5 kilobases) and are characterised by low immunogenicity, as 
shown in in vivo and ex vivo pre-clinical studies (Modlich et al., 2009; Montini 
et al., 2006). Lentiviral vectors have been used to deliver micro / mini-
dystrophin in vivo via intramuscular injection, showing successful genetic 
correction although with a low efficiency (Kimura et al., 2010; Kobinger et al., 
2003). Consequently, these vectors have been exploited to develop ex vivo 
gene therapy strategies. In these approaches muscle progenitors, isolated 
from dystrophic animals have been genetically corrected as above. Upon 
transplantation in dystrophic recipients, the expression of missing protein 
was restored (Bachrach et al., 2004; Li et al., 2005; Pichavant et al., 2010; 
Quenneville et al., 2007). Although this approach might represent a valid 
platform for the development of an autologous stem cell-gene therapy, in vivo 
studies in DMD dogs have shown that micro-dystrophin does not replicate all 
of the essential functions of the full-length dystrophin (Sampaolesi et al., 
2006). On the other hand, lentiviral vectors could be used for ex vivo gene 
therapy studies of other muscular dystrophies such as LGMD2D. Recently, 
we have transduced via a lentiviral vector the full cDNA of the α-sarcoglycan 
(disrupted in LGMD2D patients) in myogenic cells derived from patient-
specific induced pluripotent stem cells (iPSCs). We subsequently 
transplanted these cells into ad hoc generated α-sarcoglycan-null 
immunodeficient mice (Sgca-null / scid / beige an animal model for LGDM2D 
disease optimised to improve the xenograft efficiency) where they restored 
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the α-sarcoglycan protein expression and the reconstitution of the DAPC 
ameliorating the phenotype of the animals (Tedesco et al., 2012).  
Although lentiviral vectors are currently in use for gene therapy-based 
clinical trials (Aiuti et al., 2013; Biffi et al., 2013), their use is hampered by the 
risk of insertional mutagenesis (unfavourable integration in the host genome). 
To circumvent this problem, non-integrating lentiviral vectors have been 
recently generated based on the inactivation of the integrase (IDLV) (Matrai 
et al., 2011). This system is highly attractive for gene transfer in post-mitotic 
tissues such as muscles even though the levels of expression and 
transduction efficiency are generally low (Kaufmann et al., 2013; Kymalainen 
et al., 2014). However, a level of dystrophin production as low as 30% is 
reported to be sufficient to prevent muscular dystrophy in healthy mice and 
humans (Neri et al., 2007; Wells et al., 1995). For these reasons, the use of 
non-viral vectors for gene-transfer based therapies for muscular dystrophies 
can be considered as a valid alternative for gene replacement to overcome 
the limitations mentioned above. 
Non-viral vectors evoke only limited immune response and allow 
transfer of genetic material of larger sizes, such as the dystrophin cDNA of 
14 kilobases and even its whole locus of 2.4 megabases. These features 
allowed the use of these vectors in various gene therapy approaches, in 
particular for diseases caused by mutations in large genes such as DMD. 
Naked plasmids have been the first kind of these vectors considered 
attractive for gene delivery. Direct intramuscular injection of DNA constructs 
encoding for the full-length dystrophin, showed no adverse events in DMD 
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patients. However this approach was limited to a defined area and the 
expression of the protein was not sustained; in addition intra-muscular 
injection elicits a strong immune reaction against the transgene (Romero et 
al., 2004). Hydrodynamic limb vein injections have been suggested as an 
alternative to the intramuscular injections (Herweijer and Wolff, 2007). By 
applying these techniques, pre-clinical studies in dystrophic mice showed the 
restoration of the full-length dystrophin into the lower limbs and long-term 
protection of skeletal muscles (Zhang et al., 2010). Interestingly, studies on 
dose-response in rodents and nonhuman primates reached a transfection 
efficiency of 20-36%. These numbers are potentially sufficient to support the 
application of this method for possible therapeutic treatments of patients 
affected by DMD and other muscular dystrophies (Hegge et al., 2010; 
Wooddell et al., 2011). 
Alternative non-integrating and non-viral vectors are the human 
artificial chromosomes (HACs) (Kazuki et al., 2011; Kazuki and Oshimura, 
2011; Kouprina et al., 2013). HACs have a potentially unlimited cargo size 
and do not integrate in the host genome bypassing the risk of insertional 
mutagenesis (with possible activation of oncogenes). The use of HAC has 
been exploited for therapeutic approach for DMD where the entire 2.4 
megabases human dystrophin gene, as well as its promoter and native 
regulatory elements, have been accommodated into the HAC (DYS-HAC) 
(Hoshiya et al., 2009). Our group provided the first evidence of HAC-
mediated gene replacement therapy for DMD. Dystrophic murine 
mesoangioblasts have been genetically corrected with a DYS-HAC and 
	 59	
transplanted intramuscularly and intra-arterially into scid / mdx dystrophic 
immunodeficient mice. These genetically corrected cells supported the 
production of the human dystrophin in the engrafted skeletal muscle restoring 
a level of protein production up to 20% of control muscles, leading to a 
phenotypical and functional improvement of the dystrophic phenotype 
(Tedesco et al., 2011). Recent studies on DYS-HACs currently under 
development in our laboratory include the translation of this strategy to 
reversibly immortalised human cells (Benedetti et al., In preparation). In 
parallel, we derived myogenic progenitors from patient specific DMD iPSCs 
genetically corrected with a DYS-HAC that successfully differentiated into 
myotubes and produced human dystrophin in vitro (Tedesco et al., 2012). 
Further studies currently on going in the Tedesco laboratory will include 
transplantation studies based upon human (stem) cells containing the DYS-
HAC. The main limitation of this approach is represented by the low 
efficiency achievable in transferring the chromosome to the target cells. This 
process, named microcell-mediated chromosome transfer (MMCT) still needs 
to be optimised and the current technology makes it costly and time-
consuming. The pre-clinical studies performed so far showed stability and 
safety of the HAC. However, further studies will be required in order to see 
clinical application of this strategy (Tedesco, 2015). 
Transposons are DNA-based mobile genetic elements able to 
integrate in the target genome, and guarantee a stable and prolonged 
expression of the gene of interest, showing low immunogenicity, an improved 
safety profile of integration and a reduced risk of oncogenic mutagenesis 
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compared to viral vectors (Di Matteo et al., 2012; Doherty et al., 2012; Huang 
et al., 2010; Yant et al., 2005). Transposons safety has been recently 
evaluated in a clinical trial based on genetic engineering of T cells 
(Kochenderfer et al., 2010; Singh et al., 2013). Sustained expression of the 
transgene has been shown in various proof-of-principle studies, showing 
transposons ability to target clinically relevant cells (Di Matteo et al., 2014; 
Mates et al., 2009). Within these, human satellite cells and pericyte / 
myogenic progenitors can be genetically manipulated with transposons (Ley 
et al., 2014). Interestingly, transposons carrying micro-utrophin have been 
successfully used to genetically correct dystrophic murine iPSC-derived 
myogenic cells (Filareto et al., 2013). Unlike viral vectors, transposons are 
not able to deliver genetic material directly to the nucleus. For this reason, 
invasive delivery methods (i.e. electroporation) are required, making the 
direct use of transposons in vivo more challenging than viral vectors. 
Interesting recent studies are focusing on the use of hybrid technologies 
combining the viral delivery ability to the advantages of transposons (de Silva 
et al., 2010; Staunstrup et al., 2009; Vink et al., 2009). 
 
1.5.3. Stem / progenitor cell therapies 	
Satellite cells are considered the main player in skeletal muscle development, 
postnatal growth and regeneration of the damaged myofibres (Relaix and 
Zammit, 2012). Other myogenic progenitor cells located outside the basal 
lamina of the muscle fibres (e.g. pericytes, endothelial and interstitial cells) 
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have been shown to possess some myogenic potential in vitro and in vivo 
during growth and upon transplantation (Tedesco et al., 2010). Although the 
origin and the physiological contribution of these progenitors to muscle 
homeostasis is still unclear, lineage tracing experiments have demonstrated 
that some populations (e.g. pericytes) can contribute to the satellite cell niche 
during development and tissue regeneration This suggests a possible lineage 
relationship (or plasticity) between these cell types (Dellavalle et al., 2011).  
Among the various strategies aiming to treat muscular dystrophies, 
several cell therapy approaches based on different stem / progenitor cell 
populations are undergoing preclinical and clinical investigation. This section 
will provide an insight on the cell types known to be involved in skeletal 
muscle regeneration, mainly focussing on satellite cells and pericytes (a 
central topic for this work), also giving an overview on the other cell types 
relevant for this process. A comprehensive list of the cell types proposed as 
cell therapy tools to treat muscular dystrophies, including details on the 
delivery route, preclinical and clinical studies performed is summarised in  
Table 1.  
1.5.3.1. Preclinical and clinical studies on myoblast transplantation 	
Because of their ability of regenerating skeletal muscle, myoblasts were the 
first cell type considered for transplantation, with promising results obtained 
since the late eighties transplanting wild type myoblasts in murine models of 
muscular dystrophy and achieving a level of dystrophin expression of 30-40% 
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of control non dystrophic muscles in the transplanted extensor digitorum 
longus (EDL) muscles (Partridge et al., 1989). In light of these preclinical 
achievements, several groups performed the clinical trials based on myoblast 
allogeneic transplantation in Duchenne Muscular Dystrophy (DMD) patients in 
the early nineties (Gussoni et al., 1992; Karpati et al., 1993; Tremblay et al., 
1993b). These trials showed safety but very limited efficacy: death of injected 
cells and host immune-rejection were identified as the main causes of the 
poor outcome. This was confirmed following additional preclinical studies, 
showing improved engraftment upon immunosuppression (Kinoshita et al., 
1994; Morgan and Partridge, 1992; Vilquin et al., 1994). To investigate this 
further and assess the efficacy of a syngeneic approach, a proof of principle 
transplantation was performed in twin monozygotic girls carrying Duchenne 
muscular dystrophy (Tremblay et al., 1993a). Mendell and colleagues then 
attempted to improve engraftment efficiency combining myoblast 
transplantation with a strong immunosuppressive regime. The achievements 
obtained with this strategy were far below the expectations, leading to a 
maximum of 10% donor-derived dystrophin-positive myofibres in one single 
patient out of 12 treated (Mendell et al., 1995). In addition to the issue of host 
immune-rejection, myoblast transplantation failures have been mainly 
ascribed to high cell-mortality rate upon transplantation and to the poor 
migration ability of these cells (Law et al., 1992; Partridge, 2002; Skuk et al., 
2007b). More recently, intramuscular transplantation of myoblasts has been 
performed in patients affected by oculopharyngeal muscular dystrophy 
(OPMD) in a phase I / IIa clinical trial (Perie et al., 2014). In this particular 
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pathology, caused by heterozygous mutation in the gene encoding poly(A)-
binding protein-2 (PABPN1), small muscles of the face and neck are 
specifically affected by the degeneration. Autologous myoblasts were isolated 
and cultured from less affected muscles (quadriceps or sternocleidomastoid) 
and transplanted in the pharyngeal muscles. The encouraging results 
achieved with local administration of myoblasts are paving the way to a 
possible novel treatment for this disease, though more stringent controls will 
be needed. However, this approach is so far inapplicable for DMD patients 
that require treatment of large muscular districts. Different groups have 
attempted to treat a larger area of the muscles, for example by performing 
clusters of intramuscular myoblast injections using grids of needles at a 
distance of 1mm each. This technique, named high-density injection (Skuk et 
al., 2007a), is far from solving the issue of myoblast migration. Moreover, the 
damage induced by the multiple injections (and the consequent appearance 
of fibrotic and inflammatory infiltrate) might even outweigh the advantage of 
having more and better-distributed cells in the transplanted muscle. Notably, 
this system does not allow the treatment of the diaphragm, one of the mostly 
affected muscles and responsible for respiratory failure in DMD patients.  
An ideal delivery route to target all the muscle districts of the body would be 
to exploit the circulatory system. Although intravenous injection would be the 
simplest to approach, cells administered via this route will need to get through 
the filter organs (liver, kidney and lungs) causing a premature trapping before 
they reach their target organ (the skeletal muscles). For this reason, intra-
arterial injection has been considered as a preferential route, offering the 
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possibility of firstly targeting the muscles, in a loco-regional fashion. However, 
myoblasts are considered unable to cross the blood vessel wall upon 
systemic delivery, therefore limiting their use for the treatment of patients 
affected with systemic myopathies (Sampaolesi et al., 2003). In light of the 
poor results achieved with myoblast-based clinical trials, various groups have 
looked to alternative cell types, for the development of novel strategies to 
treat muscular dystrophy patients. 
	
1.5.3.2.  Other myogenic cell types 
 
To overcome the limitations that impede the clinical use of satellite cells and 
myoblasts for cell therapy purposes, other myogenic progenitors isolated from 
various tissues have been investigated exploiting the use of tissue-specific 
transgenic markers (Cossu, 1997). Diverse cell types have indeed been 
demonstrated to undergo myogenic differentiation (for a recent review, see 
Benedetti et al., 2013). Exposure to the myogenic regulator MyoD (via 
transfection, co-culture or transplantation in the muscle environment) has 
been indicated as the dominant factor able to direct these cells towards the 
myogenic lineage.  
The only ectodermal cells that have been shown to have some 
myogenic potential when co-cultured with skeletal myoblasts or upon 
intramuscular transplantation have been neural stem cells (Galli et al., 2000). 
The presence of cells positive for the early myogenesis marker Myf5 within 
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the spinal cord and in the brain, suggested that a latent myogenic potency 
might be present in some of these cells and that is possible to restore it by 
exposing these cells to the muscle environment (Tajbakhsh et al., 1994). 
In 1998 it was reported that bone marrow-derived cells have limited 
myogenic potential. The bone marrow-derived cells of donor transgenic 
animals carrying the nuclear LacZ reporter under the muscle specific 
promoter Myosin light chain (MLC3f), were transplanted into irradiated 
recipient animals. The muscles of these recipients were subsequently injured, 
and regenerated muscles showed expression of the bone marrow-derived 
beta galactosidase, indicating unequivocally bone marrow contribution to the 
tissue regeneration (Ferrari et al., 1998). This study highlighted for the first 
time the possibility (although with a very low efficiency) of recruiting 
circulating cells to the myogenic lineage. Further preclinical studies 
underlined that the efficiency of this phenomenon was too low to consider 
possible therapeutic applications (Ferrari et al., 2001; Gussoni et al., 1999). 
Interestingly this phenomenon has also been observed, again with a very low 
efficiency, with the presence of donor-derived nuclei in the muscles of 
patients that received bone marrow transplantation (Gussoni et al., 2002).  
CD133 positive cells are a circulating population, ascribed to the 
haematopoietic stem cell compartment that has been reported to have 
myogenic potential (Torrente et al., 2004). These cells are able to contribute 
to muscle regeneration and to the satellite cell pool upon transplantation in a 
murine model of DMD (Benchaouir et al., 2007; Meng et al., 2014). A 
preliminary clinical trial performed in 2007 demonstrated the safety of 
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autologous CD133-positive cells transplantation (Torrente et al., 2007). 
Patient recruitment for a follow-up phase II clinical trial based on the 
transplantation of these cells is currently on going. 
Muscle derived stem cells (MDSCs) have been isolated from skeletal 
muscle tissue using different techniques. These cells share some markers 
with other myogenic progenitors (such as satellite cells and mesoangioblasts) 
and have been transplanted in murine models of muscular dystrophy with 
variable outcome (Asakura et al., 2002; Gussoni et al., 1999; Meng et al., 
2011; Qu-Petersen et al., 2002) and upon intraarterial delivery in dystrophic 
dogs (Rouger et al., 2011). Although these are interesting findings, MDSCs 
have not yet stepped into clinical experimentation.  
PW1 positive interstitial cells (PICs), have been identified by Sassoon’s 
group in the mouse as a subset of cells located in the muscle interstitium and 
capable of contributing to muscle growth, regeneration and to replenish the 
satellite cell pool. Lineage tracing experiments have shown that these cells do 
not share the origin with satellite cells (Mitchell et al., 2010). This study 
revealed the presence of PW1 positive cells with similar features, in different 
adult tissues (i.e. central nervous system, skin and bone). It has been then 
suggested the possibility of using PW1 as a marker for tissue-specific self-
renewing progenitor cells (Besson et al., 2011). More recently, PW1 was 
found expressed also by mesoangioblasts, regardless of the species of origin 
and age of isolation (Bonfanti et al., 2015). This study showed also that PW1 
expression is required for mesoangioblasts engraftment and extravasation. 
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1.5.3.3. Mesoangioblasts as therapeutic tool to treat muscular 
dystrophies 	
Mesoangioblasts are considered the in vitro counterpart of post-natal skeletal 
muscle Alkaline Phosphatase-positive pericytes. These cells have been 
proposed as an alternative to myoblasts for cell therapy protocols aiming to 
treat skeletal muscle diseases (Sampaolesi et al., 2005). At variance with 
myoblasts, mesoangioblasts have been shown to be capable of crossing the 
vessel wall upon intra-arterial delivery, actively contributing to muscle 
regeneration and ameliorating the dystrophic phenotype of murine and canine 
models of muscular dystrophy (Sampaolesi et al., 2006; Sampaolesi et al., 
2003). These works indicated also that these cells are easily transduced with 
lentiviral vectors, making them suitable for gene and cell therapy approaches. 
Following these studies, Dellavalle and colleagues showed that 
mesoangioblasts could be also isolated from the human skeletal muscle, 
genetically corrected and engrafted in a murine model of DMD (Dellavalle et 
al., 2007). These cells, distinct from satellite cells, showed the presence of 
some pericyte markers (i.e. NG2 and AP) (Dellavalle et al., 2007; Tonlorenzi 
et al., 2007). Based upon these findings a series of studies investigated the 
possible applications of mesoangioblasts for other forms of muscular 
dystrophy (Diaz-Manera et al., 2010) and to correct aged dystrophic muscles 
(Gargioli et al., 2008) and cardiac defects (Galli et al., 2005). Notably, in 2011 
we demonstrated the possibility of exploiting mesoangioblasts for a cell-
mediated non-viral gene replacement approach. This study provided the first 
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evidence of on the in vivo use of a HAC containing the whole human 
dystrophin locus. Genetically corrected mesoangioblasts supported human 
dystrophin expression in recipient animals, leading to a long-term functional 
amelioration of the dystrophic phenotype in scid / mdx mice (Tedesco et al., 
2011).  
As mentioned above, immunological reactions play a key relevant in 
cell muscle cell therapy (Maffioletti et al., 2014). Indeed, similarly to what was 
observed with mesenchymal stem cells (English and Mahon, 2011), adult 
human mesoangioblasts have been also reported to have an 
immunomodulatory potential, inhibiting T cell proliferation (English et al., 
2013). Allogeneic human mesoangioblasts have been shown to elicit an 
immune response only in presence of inflammatory cytokines (Noviello et al., 
2014).  
These encouraging findings have led to a first-in-man phase I / II 
clinical trial, in which allogeneic mesoangioblasts have been transplanted in 
DMD patients (“Cell Therapy Of Duchenne Muscular Dystrophy by intra-
arterial delivery of HLA-identical allogeneic mesoangioblasts”; EudraCT no. 
2011-000176-33). In light of this clinical study, a better understanding of self-
renewal potential, mechanisms of fate choice and differentiation ability of 
these cells, will have a key importance aiming to improve the outcome of 
possible cell therapy protocols exploiting this cell type.		
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1.5.3.4. Myogenic progenitors from pluripotent stem cells 	
The derivation of myogenic progenitors from embryonic stem (ES) cells and 
induced pluripotent stem (iPS) cells could represent an alternative route for 
the cell therapy of muscular dystrophies. ES cells are pluripotent stem cells 
isolated from the inner cell mass of the blastocyst and have the ability to 
differentiate into any cell type (Evans and Kaufman, 1981; Thomson et al., 
1998). However the generation of ES cell lines often involves the destruction 
of human blastocysts, although a recent study has shown the possibility to 
derive ES cells from single blastomere cells without destroying the embryo 
(Rodin et al., 2014). For this reason some ethical concerns raised from the 
use of ES cells (de Wert and Mummery, 2003).  These concerns have been 
overcome with the generation of the iPS cells (Takahashi et al., 2007; 
Takahashi and Yamanaka, 2006). iPS cells are adult somatic cells 
reprogrammed to pluripotency by the transient expression of four 
reprogramming factors octamer-binding transcription factor 4 (Oct4), kruppel-
like factor 4 (Klf4), sex determining region Y-box 2 (Sox2) and c-Myc  (2012 
Nobel Prize for Physiology or Medicine).  Differently from ES cells, iPS cells 
can be patient-specific and therefore their derivatives can be potentially more 
applicable for autologous transplantation thus avoiding immune rejection (de 
Almeida et al., 2013). Importantly, a pilot clinical study is currently on-going 
for the treatment of age-related macular degeneration to assess a first proof 
of safety in using iPS-derived cells (Nakano-Okuno et al., 2014). 
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Several protocols have been developed to derive transplantable 
myogenic cells from murine and human ES and iPS cells.  Darabi, 
Perlingeiro and co-workers reported the derivation of myogenic progenitors 
from pluripotent stem cells, exploiting a combination of the overexpression of 
myogenic determinants (Pax3 and Pax7), differentiation into embryoid bodies 
and prospective isolation via FACS sorting (Darabi et al., 2012; Darabi et al., 
2009; Darabi et al., 2008; Darabi et al., 2011a; Filareto et al., 2013). Cells 
derived with this methodology successfully engrafted in dystrophic mice and 
also showed a functional improvement of muscle function.  
Alternative approaches exploited the upregulation of the myogenic 
regulatory factor MyoD, to trigger the terminal differentiation of the cells 
(Goudenege et al., 2012; Tanaka et al., 2013; Tedesco et al., 2012; Yasuno 
et al., 2014). Among these, our laboratory published in 2012 the first protocol 
to derive myogenic progenitors from human dystrophic iPS cells without the 
use of embryoid bodies or prospective isolation (Tedesco et al., 2012). These 
cells, defined as human iPS cell-derived mesoangioblast-like cells (HIDEMs) 
have been successfully transplanted intramuscularly and intra-arterially in an 
immunodeficient murine model of LGMD2D (as detailed in Gerli et al., 2014), 
engrafting the muscles and inducing the reassembly of the DAPC on the 
myofibres membranes. Interestingly, translating this protocol to an 
intraspecific setup we achieved functional amelioration of the dystrophic mice 
phenotype, with improvements in force and motor capacity. A recent follow 
up study extended the applicability of this protocol to human ES cells and iPS 
cells cultured in feeder-free conditions (Maffioletti et al., 2015). Considering 
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my significant contribution to these developments, more details on these 
strategies are reported in this thesis in chapter 4 and the recently published 
article has been included as an appendix. Interestingly, these cells have also 
been shown able to suppress T-cell proliferation (Li et al., 2013) as observed 
in mesoangioblasts, their tissue-derived counterpart (English et al., 2013). 
More in general, safety hurdles related to the possible use of iPS-derived 
cells in cell therapy approaches include immunogenicity, genetic instability 
and residual pluripotency (Tan et al., 2014), indicating that further studies will 
be needed to reduce immunogenicity and exclude eventual tumorigenic 






























scid/mdx mice (DMD) (Dellavalle et 
al., 2007; Tedesco et al., 2011); 
sgca-null mice (LMG2D)  (Galvez et 
al., 2006; Gargioli et al., 2008; 
Sampaolesi et al., 2003); scid/BIAJ 
mice (LMG2B) (Diaz-Manera et al., 
2010);  GRMD dogs (DMD) 





 MDSCs Skeletal 
muscle 
Local mdx mice (DMD) (Cao et al., 2003; 
Gussoni et al., 1999; Qu-Petersen 
et al., 2002); mdx nude mice (DMD) 
(Meng et al., 2011); GRMD dogs 










scid/mdx mice (DMD) (Benchaouir 
et al., 2007; Torrente et al., 2004) 
Phase I: 
completed (DMD) 




 PICs Skeletal 
muscle  












Injured rats and mdx nude mice 
(DMD) (Dezawa et al., 2005); 
injured NOD/scid and scid/mdx mice 
(Crisan et al., 2008); injured Rag2-/-
ϒc-/-/C5 mice (Meng et al., 2010); 
injured nude mice (De Bari et al., 
2003); mdx mice (DMD)  (De Bari et 
al., 2003; Gang et al., 2009; Wernig 











mdx mice (DMD) (Gussoni et al., 
1999); injured scid/beige mice 
(Ferrari et al., 1998); mdx4cv mice 
(Ferrari et al., 2001); injured mice 












Table 1. Summary of the reported preclinical and clinical studies on cell 
therapy approaches to treat muscular dystrophies. *Past clinical trials 
have been summarised and reviewed in (Tedesco et al., 2010) and (Tedesco 
and Cossu, 2012). §Although this is the standard tissue to derive MSCs, 
there is reported heterogeneity with regards to the tissue from which the cells 
have been isolated in the quoted articles. ⌘Model of spinal muscular atrophy 
carrying an homozygous deletion of Smn exon 7 presenting signs of 
muscular dystrophy.  N/A: not available. This table has been updated and 







Injured scid/beige mice (Barberi et 
al., 2007); injured mdx mice (DMD) 
(Chang et al., 2009; Darabi et al., 
2008; Darabi et al., 2011b); injured 
nude mice (Sakurai et al., 2008); 
injured Rag2-/-ϒc-/- mice (Darabi et 
al., 2008); injured NSG mice and 
NSG-mdx4Cv (Darabi et al., 2012); 
Rag2-/-/mdx and injured  Rag2-/-











sgca-null/scid/beige mice (LMG2D) ; 
sgca-null mice (LMG2D) 
(Quattrocelli et al., 2011; Tedesco et 
al., 2012); injured NSG mice and 
NSG-mdx4Cv (Darabi et al., 2012); 




1.6. Cell fate plasticity 
The ability of a committed cell to change fate (trans-differentiate) towards a 
different lineage is defined as fate plasticity (Bonfanti et al., 2012).  
 
Figure 11. Schematic representation of the meaning of fate plasticity. 
The stem cell / progenitor A can trans-differentiate originating B. This 
phenomenon could be also bi-directional. 
A classic example of fate plasticity observed in patients is metaplasia. In this 
pathological condition one tissue type is partially or fully replaced by a 
different one in response to stress or abnormal stimuli (Mosby, 2009).  In the 
intestinal metaplasia of the oesophagus (Barret’s oesophagus) for example, 
the normal squamous epithelium of the oesophagus is replaced by intestinal 
columnar epithelium (Shaheen and Richter, 2009). However, whether Barret’s 
oesophagus is indeed caused by a fate switch of differentiated cells or by 
selective proliferation of undifferentiated progenitors from different origin is 
still debated (Krishnadath and Wang, 2015). 
The scientific community interest started focussing more on fate 
plasticity in the last two decades, mainly for its possible implications for 
regenerative medicine. Plasticity could indeed be re-defined as extrinsic 
factor-mediated reprogramming (Bonfanti et al., 2012).  MyoD, the myogenic 
determination gene, provided the first and most remarkable example of 
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induced lineage plasticity or, as most recently defined, reprogramming. Upon 
transfection, this single transcription factor has been shown able to induce 
skeletal muscle differentiation in non-myogenic cells (Davis et al., 1987). A 
spontaneous example of this process has been indeed reported in 1995, in a 
paper reporting spontaneous smooth to skeletal muscle trans-differentiation in 
the murine oesophagus (Patapoutian et al., 1995), although this work was 
later questioned upon lineage tracing results (Rishniw et al., 2003). A 
milestone for the field was indeed a 1998 paper demonstrating that adult 
murine bone marrow contains cells that are capable of contributing to skeletal 
muscle regeneration (Ferrari et al., 1998). Following this study, many papers 
have been published showing that different cells of adult tissue can contribute 
to the regeneration of various tissues, mainly by adapting to the recipient 
environment (Bjornson et al., 1999; Krause et al., 2001; Lagasse et al., 2000; 
Orlic et al., 2001). However, some of these results were incorrect 
interpretations of the results, in which for example direct reprogramming was 
in fact mainly due to cell fusion, instead of an actual stimulation by extrinsic 
factors (Alvarez-Dolado et al., 2003; Balsam et al., 2004; Wang et al., 2003).  
 
1.6.1. Pericyte multi-potency and plasticity  
On top of covering the pericyte functions detailed above, recent studies 
suggest that pericytes have the ability to differentiate into various mesodermal 
lineages. Pericytes have been indicated as multi-potent resident tissue 
progenitors, able to differentiate both into smooth muscle and in the various 
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mesodermal cell types composing tissue in which are located (Bianco et al., 
2008). In the kidney for example, pericytes play a crucial role during tissue 
regeneration as well as in pathologic fibrosis (Duffield and Humphreys, 2011; 
Kramann and Humphreys, 2014). Pericyte ability to differentiate into bone for 
example, opened the possibility of these cells having a role in ectopic 
calcification found in arteries and muscles (Johnson et al., 2006). Indeed, 
recent evidence linked pericytes to the muscular ossification observed in 
patients affected by fibrodysplasia ossificans progressiva (Hegyi et al., 2003). 
Additionally, in a publication where Annexin 5 was used to isolate pericyte 
cells from the brain, it was shown that these cells undergo osteogenic, 
chondrogenic and adipogenic differentiation in vitro (Brachvogel et al., 2005). 
This was further confirmed with differentiation assays in vitro and in vivo, 
performed in pericytes isolated from the retina (von Tell et al., 2006).  
On the other hand, whether different cells/progenitors could acquire a 
pericyte fate is still under investigation. Glioblastoma stem cells for example 
have been observed to acquire pericyte functions to support vascular 
stabilization during tumour growth (Cheng et al., 2013). The acquisition of 
pericyte markers and properties has also been recently reported in cultured 
embryonic myoblasts upon stimulation of Notch and PDGF signalling 
(Cappellari et al., 2013). Further details on the observation of fate plasticity 
involving skeletal muscle pericytes are detailed in the next paragraph. 
	 77	
1.6.2. Muscle pericytes and satellite cells fate plasticity  
An interesting aspect outlines the close relationship between satellite cells 
and pericytes and the possible fate plasticity across these two lineages. In a 
lineage tracing study, in which TnAP-positive pericytes were labelled with 
LacZ through a Tamoxifen-mediated Cre recombinase system, these cells 
were shown to contribute to the satellite niche, generating Pax7 positive cells 
during growth and regeneration (Dellavalle et al., 2011).  
 
Figure 12. Generation of satellite cells from AP positive pericytes 
during postnatal growth. Immunohistochemistry on pectoralis muscles 
explanted from TnAP-CreERT2:R26R mice, one week (a) and one month (b) 
after Tamoxifen-mediated Cre-recombination. The blue staining has been 
obtained via LacZ enzymatic reaction and labels the TnAP pericyte-derived 
cells; in brown are highlighted the Pax7 positive satellite cells. The insets 
show high magnification images, in which is possible to observe pericytes 
(blue arrows), endogenous satellite cells (brown arrows) and pericyte-derived 
satellite cells (green arrows). Scale bar 100 µm. Adapted from Dellavalle et al. 
(2011). 
In line with these results, b-galactosidase-labelled mesoangioblasts, 
genetically corrected with a human artificial chromosome containing the 
whole dystrophin locus, have been shown to generate Pax7 positive satellite 
cells when transplanted in dystrophic animals. These cells correctly localised 
underneath the myofibre basal lamina, replenishing the satellite cell niche 
(Tedesco et al., 2011). 
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Figure 13. Genetically corrected mesoangioblasts engraft the satellite 
cells niche upon transplantation. A. Immunofluorescence staining showing 
donor derived βGal labelled cells in a transplanted scid / mdx muscle. The 
arrow shows a donor nucleus integrated in a skeletal muscle fibre. The 
arrowhead points to a donor-derived cell, located in the satellite cell position, 
underneath the muscle fibre basal lamina, expressing the satellite cell marker 
Pax7 (scale bar 100 µm). B. The left panel shows the FACS sorting plot 
obtained upon staining of a digested transplanted muscle with SM/C-2.6 to 
isolate the donor derived satellite cell fraction (gate outlined in red). Right 
panel shows a confirmation of the donor origin with the expression of EGFP 
from the sorted cells in live imaging (top). Central panel shows the 
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immunofluorescence that confirms the expression of Pax7 co-localised with 
the EGFP. The bottom part of the panel shows a FISH confirming the 
presence of the human artificial chromosome in the isolated cells (scale bars 
50 µm, 50 µm, 4 µm). Adapted from (Tedesco et al., 2011). 
A recent publication from Cappellari and colleagues indicated for the first time 
that primary embryonic myoblasts could trans-differentiate to pericytes, 
indicating possible bi-directional lineage plasticity. Among the pathways that 
regulate this phenomenon in the embryo, this work highlighted that the Notch 
cascade, interplaying with PDGF signalling is of key importance. When 
primary embryonic myoblasts were exposed to Notch ligands and PDGF, 
known to regulate the inhibition of myogenesis and pericyte recruitment, 
these cells activated pericyte markers and started showing perivascular cell 
properties (Cappellari et al 2013).  
 
 
Figure 14. Reported evidence of fate plasticity between satellite cells / 
myoblasts and pericytes / mesoangioblasts. 
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It is therefore conceivable that the mechanisms of trans-determination (or fate 
plasticity) seen in the embryo might be preserved in the adult. Possible 
lineage plasticity between satellite cells and other myogenic progenitors, such 
as pericytes, still needs to be understood and the mechanisms driving this 
phenomenon to be elucidated.  
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1.7. Notch signalling 
Notch signalling is an evolutionary conserved cell fate regulator that plays 
essential roles in the development and homeostasis of potentially all the 
tissues of the body (Artavanis-Tsakonas et al., 1999; Kimble and Simpson, 
1997). In mammals four Notch heterodimers have been identified: Notch1, 
Notch2, Notch3 and Notch4. These receptors are large trans-membrane 
proteins. The extracellular domain of all the Notch receptors contains up to 36 
EGF-like domains repeated in tandem. These domains mediate the 
dimerisation process and in particular the domains 11 and 12 are crucial to 
inhibit cis-activation, when a Notch ligand is expressed on the same cell 
membrane (Cordle et al., 2008). Five molecules have been recognised to act 
as Notch ligands: Delta-like ligand 1, 3, 4, Jagged 1 and Jagged 2. Because 
all these Notch ligands are trans-membrane proteins, cell-to-cell interaction is 
normally required to achieve an efficient signal transduction (Gerhardt and 
Betsholtz, 2003).  
When the ligand-receptor interaction occurs, it causes a proteolytic 
cleavage operated by γ-secretase. As a result, a fragment of the Notch 
protein known as Notch intracellular domain (NICD) is released in the cytosol 
and subsequently translocate within the nucleus. Once in the nucleus, NICD 
interacts with DNA-binding proteins (such as the transcription factor RBP-J), 
which positively and negatively regulates the transcription of a wide range of 




Figure 15. Core components of the canonical Notch signalling pathway. 
The Notch ligands (DLL1, DLL3, DLL4, JAG1 and JAG2), present on the 
stimulating cell interact with the Notch family receptors (NOTCH1,2,3 and 4) 
of the recipient cell. The intracellular domain of the Notch receptor (NICD) 
undergoes a proteolytic cleavage operated by the γ-secretase and it is 
released in the cytosol. Then, the NICD translocate to the nucleus and forms 
a complex with the RBPJ protein. This is done displacing a histone 
deacetylase (HDAc)-co-repressor (CoR) complex from the RBPJ. Then, an 
activation complex, such as MAML1 and histone acetyltransferases (HAc), its 
recruited to the NICD-RBPJ complex, leading to the transcriptional activation 
of Notch target genes. 
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It has been reported that Notch has a direct role as an initiator of the fate 
choice during asymmetric cell division. During this process both Notch ligands 
and receptors can be internalised into specific endosomes that are then 
differentially distributed in the daughter cells, directly acting as a fate 
determinant (Coumailleau et al., 2009). The Notch cascade is tightly 
modulated at various developmental stages by miRNA regulation, endosome 
trafficking and transcriptional target selection. Moreover, Notch cross talk with 
other signalling cascades such as BMP and Wnt maintains a delicate 
signalling homeostasis, which is still under investigation (Shin et al., 2009).  
	
1.7.1. Roles of notch in the vasculature 
Notch activity regulates embryonic vascular development, angiogenesis, adult 
vasculogenesis and arterial-venous specification (Hofmann and Iruela-Arispe, 
2007; Regan and Majesky, 2009). Cell-to-cell interactions between pericytes 
and endothelial cells have been demonstrated to be sufficient to induce 
Notch3 up-regulation both in pericytes and vascular smooth muscle cells (Liu 
et al., 2009). Consistent with this, Notch3 has been reported to play a crucial 
role in pericyte and vascular smooth muscle cell survival (Liu et al., 2010; 
Walshe et al., 2011), in particular upon Delta-like ligand 4-mediated 
stimulation (Stewart et al., 2011). Indeed, mice with specific endothelial 
ablation of RBP-J showed impaired pericyte adhesion, reduced pericyte 
coverage of the blood vessels and a high frequency of perinatal haemorrhagic 
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events, confirming that Notch signalling has role in pericyte survival and cell-
adhesion to the endothelial cells (Li et al., 2011; Winkler et al., 2011b).  
 
1.7.2. Notch in skeletal muscle development and homeostasis 	
Notch signalling also plays a major role during skeletal muscle differentiation, 
from the early stages of the myogenic specification in the embryo through to 
involvement in postnatal muscle regeneration. During development, 
oscillatory waves of Notch signalling contribute in defining the antero-
posterior patterning of somites (Lewis et al., 2009). Active Notch signalling 
has long been known to suppress myogenic differentiation. This has been 
observed in the murine myoblast cell line C2C12 (Kopan et al., 1994; Lindsell 
et al., 1995; Nofziger et al., 1999) and in primary satellite cells (Wen et al., 
2012) where it acts with various mechanisms among which repression of the 
myogenic differentiation gene MyoD is one of the most studied (Buas et al., 
2010; Hirsinger et al., 2001). In adult muscle, Notch regulates satellite cell 
activation during quiescence, niche colonisation and myogenic differentiation 
(Brohl et al., 2012; Conboy and Rando, 2002; Delfini et al., 2000; Mourikis et 
al., 2012; Mourikis and Tajbakhsh, 2014).  
Notch signalling is crucial for normal developmental myogenesis. 
Indeed, animals with induced mutations in Notch Delta ligand 1 (DLL1) or in 
its downstream transcriptional mediator Rbpj present hypotrophic muscles 
and lack myogenic progenitors. Depletion of Notch signalling leads to a 
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premature exhaustion of the satellite cell pool, leading to an impairment of 
muscle regeneration (Schuster-Gossler et al., 2007; Vasyutina et al., 2007). 
On the other hand repeated injuries in animals carrying mutations of Notch3 
lead to muscle hypertrophy and to an increase in the number of muscle 
satellite cells indicating the presence of compensatory mechanisms (Kitamoto 
and Hanaoka, 2010).  
Intramuscular injections of a Notch1 antibody activated Notch 
signalling, allowing the rescue of regenerative defects observed in aged 
muscles (Conboy et al., 2003) while sustaining Notch activation (via Delta 
Ligand 1; DLL1) in canine satellite cells during in vitro expansion improves 
their engraftment ability by promoting quiescence (Parker et al., 2012a). A 
recent report from Quattrocelli and colleagues demonstrated that the Notch 
cascade regulates also mesoangioblasts activity. DLL1-mediated notch 
depletion lead indeed to a reduction in mesoangioblasts engraftment ability 
while its activation has an opposite effect (Quattrocelli et al., 2014).  
Notably, the above mentioned publication by Cappellari et al. showed 
that embryonic myoblasts undergo a fate switch towards the perivascular 
lineage upon DLL4 and PDGF-BB stimulation, implying that bidirectional 
plasticity between these two cell types is present in the embryo (Cappellari et 
al., 2013). The interplay between Notch and PDGF, and the mechanisms and 
roles of PDGF and its receptors, relevant for this project, are detailed in the 
next section.	  
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1.8. PDGF signalling 
 
Platelet derived growth factor (PDGF) was one of the first growth factors 
identified (Paul et al., 1971). This molecule mediates cell proliferation and 
plays a significant role during the angiogenesis, where it acts as a potent 
mitogen on fibroblast, smooth muscle and other cell types (Heldin, 1992). The 
PDGF family is divided in PDGF-A and PDGF-B according to the composition 
of their polypeptide chains. These chains are formed of a series of 100 amino 
acid residues with a 60% homology between the two types (Heldin and 
Westermark, 1999). Part of this chain is similar to the ones observed in the 
VEGF family (Joukov et al., 1997).  PDGF-A and B associate in hetero- and 
homo-dimers (i.e. PDGF-AA, PDGF-BB, PDGF-AB) able to bind to three 
dimeric receptors: PDGFrα, PDGFrαβ and PDGFrβ. PDGF-AA has been 
reported active only on α-receptors, AB works on both α- and αβ-receptors 
while PDGF-BB is effective on all the three receptors (Hammacher et al., 
1989; Kanakaraj et al., 1991; Seifert et al., 1989). These receptors are 
localised on the cell membrane and when activated show a tyrosine kinase 
activity (Matsui et al., 1989). Different factors have been reported to regulate 
isoform specific PDGF signals. IL1α, TNFα and basic-FGF for example 
specifically upregulate the receptors binding PDGF-AA (Bonner et al., 1996; 
Centrella et al., 1992), while IL1 and TGFβ induce a downregulation of the 
beta receptors (Bonner et al., 1995; Xie et al., 1994).  
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Ligand-receptor interaction activates PDGF signalling transduction. 
The ligand induces a conformational change that starts the intracellular signal 
transduction, mediated by proteins that dock to the tyrosine kinase domain 
upon via SH2/SH3 domains. This activation mediates the one of different 
signalling transduction pathways involving PI3-kinases, Phospholipase C, 
Src, GRB2, GTPases activating protein and Stat3 (Darnell, 1997; Erpel and 
Courtneidge, 1995; Heidaran et al., 1993; Hu et al., 1995; Kamat and 
Carpenter, 1997; Vanhaesebroeck et al., 1997). It is difficult to dissect the 
precise role of all these different effectors, however the main ascribed to 
these signalling pathways have been linked to cell division, actin 
reorganisation, chemotaxis and to the Akt/PKB anti apoptotic effect (Heldin 
and Westermark, 1999).  
In addition to its mitogen activity, PDGF has a role in tissue 
remodelling, cell migration and differentiation (Hoch and Soriano, 2003). 
PDGF is considered a required element for the regulation of fibroblast 
proliferation, in particular during the wound healing process (Pierce et al., 
1991). For this reason, PDGF overexpression has been linked to the 
development of different diseases, among which are atherosclerosis and 
fibrotic disorders (Abboud, 1995; Trojanowska, 2008). 
PDGF-B and its receptor PDGFrβ are essential for pericyte recruitment 
in the CNS, kidneys and for the cardiovascular system (Leveen et al., 1994; 
Lindahl et al., 1997; Tallquist et al., 2003). During vessel growth, endothelial 
cells directly recruit mesodermal progenitors to the pericyte fate by secreting 
PDGF-BB (Hellstrom et al., 1999). In the embryo, Notch signalling works 
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together with PDGF-BB in driving fate choice between the smooth and 
skeletal muscle lineages, where it induces an up-regulation of PDGFrβ, 
leading to an increased cell response to PDGF-BB stimulation (Jin et al., 
2008). Importantly, it has been recently shown that a combinatory treatment 
with DLL4 and PDGF-BB induces a lineage switch in embryonic myoblasts 
towards the pericyte lineage (Cappellari et al., 2013). These results set the 
basis for the hypothesis behind this thesis. 
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1.9. Other pathways involved in skeletal muscle 
regeneration and recruitment of mesodermal progenitors 
to the pericyte fate. 
 
Several signalling pathways regulate recruitment of mesodermal progenitors 
to the pericyte fate. In particular, tissue culture studies have shown that the 
cytokine TGFβ1, in combination with PDGF, is involved in the recruitment of 
mesenchymal precursors to the smooth muscle lineage (Hellstrom et al., 
1999; Hirschi et al., 1998). Moreover, TGFβ1 has been shown to induce 
vessel maturation, inhibiting endothelial cell proliferation and migration (Sato 
et al., 1990). Noggin, expressed from the newly formed myofibres in the 
embryo, acts in contrast with BMP 2 / 4 produced from the vessels (i.e. aorta), 
to play a fundamental role in mesodermal progenitors recruitment to the 
muscle fate (Ugarte et al., 2012). The progression from commitment to 
terminal differentiation of satellite cells relies on a temporal switch from Notch 
to Wnt signalling (Tsivitse, 2010).	The crosstalk between these two pathways 
involves the activity of Gsk3β, that maintains Notch signalling by inhibiting the 
Wnt3a cascade (Brack et al., 2008). Notch has also been linked to TNF 
signalling. DMD patients show increased levels of TNF-α, which has also 
been proposed as a novel marker of the disease (Abdel-Salam et al., 2009). 
This signalling pathway has been shown to down-regulate Notch1 mRNA 
levels and inhibit the self-renewal capacity of cultured murine myoblasts 
(Acharyya et al., 2010).  
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1.10. Stem cell self-renewal  
Self-renewal is defined as a series of cell division cycles that repeatedly 
generate at least one daughter cell equivalent to the mother with latent 
capacity for differentiation. This concept is considered to be a defining 
property of a stem cell (Smith, 2006).  
 
Figure 16. Schematic representation of the meaning of self-renewal. The 
“stem cell” A undergoes a cycle of asymmetric cell division that generates two 
daughter cells. Of these two cells, A is identical to the mother and will 
replenish the stem cell pool while B represents a more committed progenitor. 
In light of this definition, self-renewal is a phenomenon strictly linked to 
another fundamental concept of stem cell biology: asymmetric cell division 
(Figure 16). This property defines a cell able to generate progenies with 
distinct fate from a single mitosis (Jan and Jan, 1998). This oriented cell 
division may position daughter cells in different microenvironments (or 
anatomical compartments). Intrinsic determinants (i.e. transcription factors) 
may also be segregated into only one daughter cell. This property is observed 
in some, but not all stem cells and can occur in other types of progenitors 
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(Smith, 2006). Indications of self-renewal have been observed in different 
tissues including intestine, epidermis and testis (Simons and Clevers, 2011).  
Serial transplantation of clonal stem cell populations is recognised as 
the most stringent assay to study stem / progenitor cell regenerative potential. 
This assay provides a thorough outcome for the investigation of the self-
renewal capacity of a stem cell population. Serial transplantation assays have 
been utilised to prove the self-renewal potential of hematopoietic, skeletal and 
epidermal stem cells (Blanpain et al., 2004; Claudinot et al., 2005; Sacchetti 
et al., 2007) In the skeletal muscle field there is increasing evidence indicating 
that satellite cells retain self-renewal potential, together with other stem cell 
properties, such as asymmetric distribution of cell fate determinants and DNA 
strands (Kuang et al., 2007; Shinin et al., 2006). Recently, satellite cells have 
been formally proved capable of self-renewal with a serial transplantation 
assay (Rocheteau et al., 2012).  
Various methods have been proposed aiming to isolate satellite cells 
via flow cytometry (Conboy et al., 2010; Motohashi et al., 2014; Pasut et al., 
2012). The group of Sinhichi Takeda, reported in 2004 the possibility of 
isolating quiescent (i.e. non-committed and non-proliferating) satellite cells 
from digested adult skeletal muscle via fluorescence-activated cell sorting 
(FACS), using a monoclonal antibody against the surface antigen SM/C-2.6 
(Fukada et al., 2004; Fukada et al., 2007; Ikemoto et al., 2007). Utilising this 
antibody, it has been possible to isolate donor-derived satellite cells from 
muscles transplanted with mesoangioblasts (Tedesco et al., 2011).  
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Although pericytes can give origin to Pax7-positive satellite cells during 
development (Dellavalle et al., 2011), whether myogenic progenitor different 
from satellite cells (i.e. mesoangioblasts) could generate myogenic 
progenitors capable of self-renewal still needs to be rigorously elucidated. 
Understanding the self-renewal potential of mesoangioblasts and their 
progeny is particularly relevant considering the role that self-renewal has in 








CHAPTER 2:  
2. OBJECTIVES OF THE RESEARCH 
Aim 1: Investigation of satellite cell fate plasticity 
The main aim of my PhD project has been to investigate the fate plasticity of 
adult muscle satellite cells, focussing on the possibility to directly reprogram 
these cells towards the pericyte lineage.  
Indications of fate plasticity between these two lineages have been 
reported in the literature. In particular, pericytes and mesoangioblasts have 
been shown to contribute to the satellite cell niche during growth, tissue 
regeneration and upon transplantation (Dellavalle et al., 2011; Tedesco et al., 
2011). On the other hand, the only available evidence that this plasticity could 
be bidirectional is restricted to primary embryonic myoblasts stimulated in 
culture with a combination of cytokines. Upon treatment, these cells were able 
to activate pericyte genes and acquire rudimental pericyte features, providing 
the first evidence in this direction (Cappellari et al., 2013). Our hypothesis is 
that primary adult satellite cells and myoblasts may retain a level of plasticity 
similar to the one observed in the embryo.  
The recruitment of adult cells to the perivascular fate and the idea that 
these cells might act as resident progenitors in various tissues has been 
hypothesised and indicated in some past work (Abou-Khalil et al., 2010; 
Bianco and Cossu, 1999; Cossu and Bianco, 2003; Minasi et al., 2002). 
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Notch and PDGF signalling have been shown to have a crucial role both in 
vascular homeostasis and in skeletal muscle biology, where cross-talk 
between these pathways regulates tissue regeneration, stem cells 
quiescence and activation. Delta-like ligand 4 is a Notch signalling stimulating 
molecule that is physiologically produced by the endothelial cells during 
vessel formation. In combination with a PDGF-B dimer (PDGF-BB), DLL4 is 
involved in the recruitment of mesodermal cells to the pericyte fate during 
vessel formation (Hellstrom et al., 1999; Stewart et al., 2011). Nevertheless, 
whether this process is active in adult skeletal muscle homeostasis and 
regeneration still needs to be elucidated. 
Therefore it is conceivable that treating adult muscle satellite cells with 
DLL4 and PDGF-BB could induce in these cells a direct reprogramming to the 
pericyte-like fate. To our knowledge, at the time of this thesis, there are no 
examples of this in the literature. 
If true, this work will provide indications of bi-directional fate plasticity 
between these two lineages, and insights into skeletal muscle homeostasis 
and regeneration. Importantly, the possibility of skeletal-to-smooth muscle 
lineage reprogramming could also be exploited to give to the cells beneficial 
properties for cell therapy purposes. For example, treated myoblasts might 
acquire the ability to cross the blood vessel wall upon systemic delivery (a 
particular property of pericyte-derived mesoangioblasts), while retaining the 
remarkable myogenic memory that characterises satellite cells and 
myoblasts.  
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The cellular response to the treatment has been characterised firstly by 
analysing phenotypic variations in terms of morphology, activation of pericyte 
markers, proliferation and the ability to undergo myogenic differentiation. The 
gene expression profile of the cells will then be assessed via quantitative real 
time PCR (qRT-PCR) analyses, to investigate variations in the genes targeted 
by the stimulation as in satellite cell and pericyte markers. Treated cells will 
then be tested for functional pericyte properties in vitro, investigating their 
ability to support endothelial network formation and stabilisation. Additional 
tests will include the assessment of the cell migration ability toward an 
endothelial cell layer in vitro. Tumour formation assays will ensure that the 
treatment does not alter the “non-transformed” state of the cells. 
Transplantation experiments will be performed with the aim of assessing the 
engraftment potential of these cells. Moreover, proof of principle experiments 
will be also performed, aiming to understand if reprogrammed cells gain the 
ability to migrate through the vessel wall in vivo.  
If translated to human cells, this direct reprogramming mechanism may 
have the potential to produce a more clinically relevant stem cell product that 
shares both the beneficial properties of both satellite cells and pericytes. This 
might have a significant impact for the development of novel cell therapy 
strategies aiming to treat muscular dystrophies.  
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Aim 2: Understanding the self-renewal potential of 
mesoangioblast-derived cells. 
Previous observations showed that pericytes and mesoangioblast derivatives 
are capable of repopulating the satellite cell niche, generating Pax7 positive 
cells that correctly localise underneath the myofibres basal lamina during 
muscle regeneration and upon transplantation (Dellavalle et al., 2011; 
Tedesco et al., 2011). Tajbakhsh and co-workers have recently provided a 
formal demonstration of the long-term self-renewal capacity of satellite cells, 
combining lineage tracing and label retaining assays in an elegant serial 
transplantation approach (Rocheteau et al., 2012).  
Whether pericyte-derived cells are able to self-renew as demonstrated 
for bona-fide muscle stem cells still need to be elucidated. A series of 
experiments performed in our laboratory have indicated that transplanted 
mesoangioblasts are able to sustain long-term engraftment (up to 8 months) 
and a subsequent round of regeneration upon acute myoinjury. This 
publication also showed the possibility of isolating donor-derived satellite-like 
cells from the transplanted muscles (Tedesco et al., 2011). Taken together, 
these data provided preliminarily indications on the self-renewal ability of 
pericytes / mesoangioblast-derived cells in vivo. However, this phenomenon 
needs to be formally proved via serial transplantation assays. 
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Based upon the above observations, our hypothesis is that upon 
transplantation, mesoangioblasts are able to generate cells that are capable 
of self-renewal.  
To this aim, we performed a series of serial transplantation 
experiments to assess the self-renewal of these mesoangioblast-derived cells 
in vivo. Intramuscular injection was chosen over intra-arterial delivery for 
feasibility reason, given the complexity of the microsurgical technique 
required to transplant cells intra-arterially in mice (Gerli et al., 2014). 
Transplanted muscles will be subject to a mechanical and enzymatic 
digestion protocol implemented to isolate mononuclear cells from 
transplanted skeletal muscles. Donor derived cells, will be then subjected to 
FACS sorting purification exploiting also a monoclonal antibody (SM/C-2.6) 
reported to allow the separation of satellite from non-satellite cells (Fukada et 
al., 2004). Isolated cells will then be serially transplanted to investigate their 
potential in vivo (Figure 17).  
 
 
 Figure 17. Schematic representation of the serial transplantation 
strategy. Mesoangioblasts (MABs) will be transplanted intramuscularly in 
dystrophic mice. One month after transplantation, muscles are harvested and 
digested. The single cell suspension obtained will be FACS-sorted for SM/C-
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2.6 to identify and isolate mesoangioblast-derived satellite cells, which are 
subsequently cultured and serially transplanted intramuscularly into a new 
recipient (Illustrations obtained from Servier Medical Art).  
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CHAPTER 3:  
3. MATERIALS AND METHODS 
3.1. Cell isolation and culture 	
Primary satellite cells were isolated from adult muscles, mechanically 
fragmented and digested twice in an HBSS solution containing Collagenase D 
(0.1%; Roche, Switzerland; 11088882001), Dispase (0.24U / ml; Gibco, USA; 
17105-041) and DNAse (0.1mg / ml; Roche, Switzerland; 11284932001) for 
20 minutes at 37°C in a shaking waterbath. The digestion product was filtered 
through a 40 µm strainer (Corning, USA; 352340) and enzymatic activity was 
inhibited with 20% of Foetal Bovine Serum (FBS; Gibco, USA; 10270-106). 
The cell suspension was then centrifuged for 30’ at 1100rpm in a centrifuge, 
pre-cooled to 4° C. The pellet was washed twice in Phosphate-Buffered 
Saline (PBS, Gibco, USA; 10010015), then re-suspended in culture medium 
and pre-plated on cell culture plastic and incubated for one hour at 37° C 5% 
CO2 to remove eventual contaminant fibroblasts and enrich the floating 
fraction of satellite cells, typically low adherent on uncoated cell culture plastic. 
The supernatant containing the satellite cells was then collected and 
transferred to collagen-coated dishes (Sigma-Aldrich, USA; C8919) at a 
density of 1.2x103 cells / cm3. The cells were then cultured at low density in 
an ad-hoc defined satellite cell media (DMEM-F / 12, Gibco, USA, 11039-21; 
10% Horse Serum, Euroclone, Italy, ECS0090L; 20% FBS and 5ng / ml 
basic-fibroblast growth factor, 5ng / ml b-FGF, Gibco, USA, AA10-155; 1% 
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penicillin / streptomycin / gentamicin). Mesoangioblasts / Pericytes utilised in 
this study were described, isolated and maintained in culture in DMEM 
(GIBCO, USA; 21063-029) containing 20% FBS as reported previously 
(Dellavalle et al., 2011; Tedesco et al., 2011; Tonlorenzi et al., 2007). 
3.2. Fluorescence-activated cell sorting purification 	
Fluorescence activated cell-sorting purification of the Pax7nGFP (satellite 
cells), TnAP-YFP (freshly isolated pericytes) positive cells from bulk 
preparations were performed with a FACS Aria III (Becton Dickinson, USA) at 
the Institute of Child Health flow cytometry facility. When donor-derived 
satellite-like cells have been re-isolated from transplanted muscles (i.e. for the 
self-renewal project) these have been labelled using a biotinylated SM/C-2.6 
monoclonal antibody (kindly provided by Prof. Shin’ichi Takeda, National 
Centre of Neurology and Psychiatry, Kodaira, Tokyo, Japan), as previously 
described (Fukada et al., 2004; Tedesco et al., 2011). After two washes in 
PBS (Gibco, USA; 10010015) containing 1% FBS and 0.5 mM EDTA (Gibco, 
USA; 15575-020), freshly digested cell suspensions were incubated with the 
SM/C-2.6 primary antibody, washed in PBS and incubated with the 
appropriate APC, PE or PeCy7-conjugated streptavidin. Cell sorting has been 
performed with a MoFlow (Beckman coulter, USA) or FACS Aria III (Becton 
Dickinson, USA) sorter. 
3.3. DLL4 and PDGF-BB treatment 	
Murine recombinant delta-like ligand 4 (DLL4; R&D, USA: 1389-D4) was 
resuspended to a final concentration 10 µg / ml in sterile PBS containing 0.1% 
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wt / vol Bovine serum albumin (BSA; Sigma-Aldrich, USA; A9418-10G) as 
carrier protein. To induce reprogramming, standard cell culture plastic flasks 
were coated with the DLL4 solution and incubated at 37° C for 45 minutes 
prior use. The cells were then seeded on the coated flasks and the cultures 
were then supplemented with 50ng / ml of PDGF-BB (Sigma-Aldrich, USA; 
P4056) daily for the first week of treatment, then every other day together 
with medium changes. One week was considered the minimum duration of 
the treatment. 
3.4. Myogenic differentiation assays 	
Myogenic differentiation assays were performed seeding the cells at a density 
of 1.2x104/cm2 as previously described (Tedesco et al., 2011). When 
confluecy was reached, the cultures were switched to a differentiation media 
(DMEM 2% Horse serum) replaced every other day for one week. For the γ-
secretase inhibitor supplementation experiments, L-685,458 (Sigma-Aldrich, 
USA; L1790) has been added to the cultures in proliferation media one day 
before starting the differentiation protocol and then every other day together 
with the differentiation media changes as previously reported (Cappellari et al., 
2013). The dishes were then fixed with 4% Paraformaldehyde (PFA; TAAB 
Laboratories Equipment, England; P001) for 5 minutes, washed in PBS and 
stored covered in PBS and refrigerated at 4°C until use for 
immunofluorescence analysis. If the cells already had a fluorescence reporter, 
the exposure to light was minimised by covering the samples with aluminium 
foil. 
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3.5. Immunofluorescence and enzymatic reaction staining 	
Cells and tissues were processed as previously reported (Tedesco et al., 
2012). Firstly a 15 minutes permeabilisation in a solution of PBS containing 
0.1% Triton (Sigma-Aldrich, USA; T8787) and 1% bovine serum albumin 
(BSA) was performed. Next, the non-specific binding sites were blocked by 
incubating the samples in PBS containing 0.1% Triton and 1% BSA, 
supplemented with 10% goat or donkey serum (Jackson ImmunoResearch 
Laboratories, USA, 005-000-121; Sigma-Aldrich, USA, D9663-10ML) for 30 
minutes. The samples were then incubated overnight at 4° C with the 
following primary antibodies: mouse anti-myosin heavy chain (Developmental 
Studies Hybridoma Bank, USA; MF20), CD31 (Developmental Studies 
Hybridoma Bank, USA; PECAM), Pax7 (Developmental Studies Hybridoma 
Bank, USA; Pax7), mouse anti alpha sarcoglycan (Novocastra, UK; NCL-a-
SARC); mouse anti-dystrophin Dys1 and Dys2 (Novocastra, UK; NCL-DYS1 
and NCL-DYS2); mouse anti-MyoD1 (Dako, Denmark; M3512), rabbit anti-
EGFP (Molecular Probes, USA; A-11122), chicken anti-EGFP (Millipore, 
Germany; AB16901), chicken anti-Laminin (Abcam, England; ab14055). To 
minimise the evaporation of the primary antibodies solution a humid 
environment was created placing a wet tissue in the box utilised for the 
staining. Following this, samples were washed twice in PBS. The samples 
were then incubated in the dark for 60 minutes at room temperature with the 
following secondary antibodies diluted 1:500 in PBS: Donkey and Goat IgG 
were used as secondary antibodies (Molecular Probes, USA; Alexa Fluor 
series), Hoechst 33342 (Sigma-Aldrich, USA; B2261) was used to highlight 
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the nuclei. Before use, secondary antibody solutions were centrifuged for 5 
minutes at 12000 RPM to eliminate eventual antibody clusters, avoiding 
collecting the precipitate at the bottom of the tubes. After the incubation and 
two PBS washes, coverglasses were mounted using fluorescent mounting 
medium (DAKO, Denmark; S302380). The samples were stored at 4°C 
minimising exposure to light until use. The imaging of the stained samples 
was performed using Leica DM and DMI 6000 optical fluorescent 
microscopes, equipped with 405, 488, 546 and 647 filters. Alkaline 
phosphatase stainings were performed on fixed cells and tissue preparing the 
staining solution following the standard procedures available in the 
manufacturer kits (Roche, Switzerland, NBT / BCIP 11681451001). X-gal 
staining was performed following the standard manufacturer procedures 
(Invitrogen, USA, B-1690). The samples were then incubated with the staining 
solution for one hour at 37° C, washed in PBS and counterstained as 
required. 
3.6. Quantitative real time PCR and gene expression 
analyses 	
RNA extraction was performed with RNeasy kits (Qiagen, Germany; 74004), 
quantified with a Nanodrop 2000 (Thermo scientific) and reverse-transcription 
with Improm RT kit (Promega, USA; A3800) using a BioRad T100 
thermocycler and following the standard manufacturers procedure. Samples 
were then processed for quantitative real time PCR using Real Time Master 
Mix (Promega, USA; A600A) on a BioRad CFX96 system. Annealing 
temperatures were adjusted to be optimal for each pair of primers (See Table 
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2 for details on the primers). qRT-PCRs were performed in triplicate on 
samples obtained from three independent experiments (with the exception of 
the one performed on purified Pax7nGFP cells for which a single cell 
preparation was available). GAPDH was used as normaliser gene for each 
run. Amplicons were then resolved by electrophoresis on a 2% agarose gel to 
confirm the fragment length. RNA extraction and amplification reactions have 
been performed in compliance with the MIQE guidelines (Bustin et al., 2013). 
Data analysis was performed with Microsoft Excel and GraphPad Prism 6 
using a standard ΔΔCt / fold increase method (Schmittgen and Livak, 2008). 
Data were presented as mean ± standard deviation (SD). Significance was 
assessed on the ΔCt values using Student’s t-test assuming two-tailed 
distribution and equal variances. Large standard deviations were observed 
trough the independent biological replicates. Therefore, to increase the power 
of the statistical analysis a Two-way ANOVA (using Fisher LSD uncorrected 
multiple) and a multiple regression analysis on the fold transformations have 
been implemented (Yuan et al., 2006).  
Gene Sequence (5’->3’) 
Annealing 
temperature (°C) 
Notch1 FW TGGACGCCGCTGTGAGTCA 55 
Notch1 REV TGGGCCCGAGATGCATGTA 55 
HesI FW ACACCGGACAAACCAAAGAC 60 
HesI REV AATGCCGGGAGCTATCTTTC 60 
Hey1 FW CACCTGAAAATGCTGCACAC 60 
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Hey1 REV ATGCTCAGATAACGGGCAAC 60 
Pax7 FW ATGTTCAGCTGGGAAATCCGGG 60 
Pax7 REV TCCCGAACTTGATTCTGAGCACTCG 60 
MyoD FW GCCCGCGCTCCAACTGCTCTGAT 60 
MyoD REV CCTACGGTGGTGCGCCCTCTGC 60 
PDGFrβ FW GCTCACGGTCTGAGCCATTC 60 
PDGFrβ REV GCTCGGACATTAAGGCTTGCT 60 
TnAP FW GTGGATACACCCCCCGGGGC 56 
TnAP REV GGTCAAGGTTGGCCCCAATGCA 56 
SM22 FW CCAACAAGGGTCCATCCTACG 60 
SM22 REV ATCTGGGCGGCCTACATCA 60 
NG2 FW ACAAGCGTGGCAACTTTATC 55 
NG2 REV ATAGACCTCTTCTTCATATT 55 
GAPDH FW AGGTCGGTGTGAACGGATTTG 60 
GAPDH REV TGTAGACCATGTAGTTGAGGTCA 60 
 
Table 2. List of the qRT-PCR primers utilised for this study. Listed in the 
table the qRT-PCR primers utilised for this study with the optimum melting 
temperature calculated using PrimerBlast.  
3.7. Endothelial network formation assay 	
Endothelial network formation assays were carried out as previously 
described (Cappellari et al., 2013; Goodwin, 2007; Tedesco et al., 2012; You 
	 106	
et al., 2014). Primary human umbilical vein endothelial cells (HUVEC) were 
maintained in culture in EGM media (Lonza, Switzerland; CC-4133) on 1% 
gelatine-coated flasks (Sigma-Aldrich, USA; G9136). HUVECs were kept 
below 70% of confluence and used up to passage 7. For the network 
formation assays, cell culture dishes were coated with 25% of reduced-growth 
factors Matrigel resuspended in phenol red-free DMEM at 37°C for 30 
minutes. HUVECs were then seeded on the Matrigel coated dishes at a 
density of 5x104 cells / cm2. After thirty minutes, the cells to be tested were 
added at a ratio of 1:10 to the HUVECs and the cultures were supplemented 
with 10 ng / ml of vascular endothelial growth factor (VEGF) (Sigma-Aldrich, 
USA; V7259) to stimulate the formation of the endothelial networks. Dishes 
were then monitored via fluorescent live imaging using a Leica DMI600b 
microscope equipped with a thermostatic chamber and an electronic CO2 
regulator. The number of network branches / 20X field (0.31 mm2) was 
quantified over time to assess the stability of the networks. The number of 
cells co-localised with the endothelial network branches was also quantified 
using image J. 
3.8. In vitro migration assay 	
In vitro migration assay was performed using the H5V murine endothelial cell 
line (Garlanda et al., 1994). H5V were grown to full confluence on 1% gelatin-
coated 8µm pore transwell membranes (BD Biosciences, USA; 353093). 
Confluence of the endothelial layers was assessed, by measuring the 
permeability of BSA with the Protein Assay Reagent Kit A-B-S (BioRad, USA) 
using an ELISA plate reader (iMark microplate reader; BioRad, USA). The 
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upper chamber of the transwell was loaded with the cells to be tested, re-
suspended in a serum-free media. The lower chamber was loaded with a 
chemoattractant medium composed of 50% fresh growth media and 50% 
myoblasts conditioned media (previously exposed for 24 hours to 
differentiated C2C12 murine myoblasts to mimic the muscle environment). 
After six hours, the membranes were gently washed in PBS and fixed for 5 
minutes in 4% PFA. The top of the membrane was scraped off with a cotton 
bud to remove the non-migrated cells. After an additional PBS wash, the 
membranes were mounted with fluorescent mounting media above glass 
microscope slides. The number of cells that migrated through the H5V 
endothelial layer was quantified by counting the number of fluorescent cells 
on the lower side of the membrane using an inverted microscope (Leica 
DMI6000B). A minimum of 30 random 20X field (0.31 mm2) / condition was 
counted per each independent experiments. 
3.9. Mice 	
All the animals used for this study were housed in specific pathogen free 
(SPF) conditions in clean ventilated racks at the UCL facility (London, United 
Kingdom). All procedures involving living animals have been approved by the 
UCL ethical committee and conformed to the Home Office regulations (ASPA 
1986), PPL 70 / 7435 and PIL 70 / 24251. The use of animals has been 
rationalised following the Home Office guidelines and implementing the 3Rs 
(Reduction, Refinement, Replacement). Pax7-nGFP mice were bred at the 
Pasteur institute (Paris, France) complying the European legislation and 
under the approval of the institutional ethical committee. 
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3.10. Intramuscular cell transplantation   	
Three to five-month-old Sgca-null / scid / beige (Tedesco et al., 2012) and 
scid / mdx (Farini et al., 2007) immunodeficient dystrophic mice were used for 
the transplantation experiments listed in this thesis. After trypsinisation 
(Trypsin-EDTA solution, Sigma-Aldrich, USA; T3924), cells were washed 
twice in PBS to eliminate the residual FBS present in the media. The final cell 
preparation was then resuspended in Ca++ / Mg++ free PBS to a concentration 
of 5x105 cells / 30ul. The skin of the animals was disinfected with a 
chlorexidine-based disinfectant. Injection was performed with a 30G needle 
syringe into tibialis anterior, gastrocnemius and quadriceps muscles. In detail 
For the tibialis anterior, 5 mm of the needle was inserted approximately 2 mm 
below the insertion of the proximal tendon (cranio-caudal direction) with a 15° 
inclination relative to the tibia and the cell suspension was slowly injected 
while retracting the needle emptying the syringe with 2 mm of the needle still 
inside the muscle. For the GC and QC, the same procedure was repeated as 
detailed for the tibialis anterior, with the main difference being the caudo-
cranial insertion of the needle 2 mm above the myotendinous junction of the 
Achilles tendon for the GC and 2 mm above the distal tendon for the QC (15° 
inclination with respect to the femur). Further details on the intra-muscular cell 
transplantation procedure are reported in a protocol paper published during 




3.11. Intra-arterial cell transplantation   	
For intra-arterial transplantation, the mice were anesthetised using 
isofluorane (2 litres / min in O2). Analgesia (Caprofen, Bayer) was 
administrated 40 minutes before the surgery to avoid to the animals further 
discomfort related to the surgical procedure. After trypsinisation (Trypsin-
EDTA solution, Sigma-Aldrich, USA; T3924), cells were washed twice in PBS 
to eliminate the residual FBS present in the media and filtered through a 
40um cell strainer to eliminate possible cell clusters from the cell suspension. 
The final cell preparation was then resuspended in Ca++ / Mg++ free PBS to a 
concentration of 5x105 cells / 50ul. After having shaved and sanitised the skin 
of the inguinal region of the mice with a chlorexidine-based disinfectant, a 5 
mm incision to access to the femoral artery was performed. The femoral 
bundle was exposed gently removing the connective tissue fascia overlaying 
it. The artery was separated from the femoral vein and nerve by gently 
introducing the tip of a forceps (or a 30 G needle) in between them and by 
progressively enlarging the hole. Transplantations were performed lifting the 
artery with one tip of a forceps and clamping it with the other tip. The artery 
was then punctured with a syringe equipped with a 30 G needle and injected 
with 50 ul of cell suspension, at a concentration of 2.5 x 105 cells / 50µl. The 
needle and the forceps were then gently removed from the artery to restore 
bloodstream in the limb. Pressure was applied with sterile gauze to avoid 
bleeding and/or cauterization was performed as required. The wounds were 
sutured and the animals monitored until recovery from anesthesia. Analgesia 
was administered for 3 additional days and the wound inspected daily for at 
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least one week. Further details on the intra-muscular cell transplantation 
procedure are reported in a protocol paper published during this PhD a copy 
of which is attached to this thesis (Gerli et al., 2014).   
3.12. Tumour formation assay 	
Tumorigenic formation assays were performed injecting subcutaneously 
immunodeficient mice with 2 x 106 cells washed in PBS as described above 
and resuspended in a volume of 100ul. After the injections, the animals were 
observed biweekly for a minimum of 2 months as a follow-up to verify the 
absence of tumour masses. At the end of the experiment, the animals were 
humanely culled and dissected to confirm the absence of tumour masses. An 
appropriate positive control for this experiment could be the subcutaneous 
injection of a tumorigenic cell line such as S180 murine sarcoma cells (ATCC, 
TIB-66). However, this control experiment has not been performed for this 
project, aiming to implement the 3Rs (reduction, refinement and replacement) 
taking in consideration that I have demonstrated to master this technique in a 
recently published article (Tedesco et al., 2012; Figure S1B). 
 
3.13. Tissue explant and processing 	
At the suited time point, transplanted mice were humanely killed following the 
schedule 1 procedures approved by the UCL ethical committee and 
conformed to the Home Office regulations (ASPA 1986). Tissues were 
explanted applying aseptic techniques and removing the muscle fascia 
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(epimysium) with the forceps.  Whenever the transplanted cells were labelled 
with a fluorescent protein, engraftment was assessed at first via direct 
fluorescent stereomicroscopy using an UV-equipped stereomicroscope 
(Leica Microsystems, Leica MZ10F). The tissue samples were then 
processed for cryopreservation as follow. 4% Tragachant gum was utilised 
as a sample holder for the inclusion. 1 g of gum was placed above a cork 
support. The tip of the muscle (possibly a tendon) was then embedded in the 
gum being careful that the myofibres were oriented vertically. The cork was 
then moved in a beaker containing 50 ml of isopentane pre-chilled in liquid 
nitrogen for one minute to achieve the snap-freezing of the specimen. The 
samples were then moved for two additional minute in liquid nitrogen to 
complete the freezing and then stored in a -80° C freezer until processing.   
Tissues were then cryosectioned with a cryostat (Leica biosystems, Leica 
CM1850) set to a temperature of -22°C and 7-10 µm thick sections were cut. 
Eight to ten replicate slides (25-40 sections / slide) were obtained from each 
tissue specimen. Slides were then placed into -80 C for long-term storage, 
and used for histological, immunohistochemistry and immunofluorescent 
stainings. For each sample, a series of sections have been collected into 1.5 
ml tube and stored at -80° C to perform molecular biology assays.  
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CHAPTER 4:  
4. PROTOCOL DEVELOPMENT 	
This section aims outline my contribution to the development of protocols 
with relevance for the field and in light of the experiments detailed in this 
thesis. In particular the first section (4.1) details refinements introduced into 
the in vivo transplantation and surgical procedures aiming to reduce its 
impact on the animal’s welfare. Section 4.2 details my contribution in the 
improvement and extension of a protocol to derive mesoangioblast-like cells 
from pluripotent stem cells. Although his protocol has marginal direct 
relevance in light of the work detailed in this thesis, this offers an alternative 
strategy to develop an efficacious cell therapy platform to treat muscular 
dystrophies. This paragraph has been included to underline that the way to 
achieve an effective treatment for these diseases is still long and my interest 
in these developments is not restricted to a single candidate technique.  
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4.1. Establishing and optimising the in vivo methodology 
of myogenic cell transplantation. 	
Together with Sara Martina Maffioletti, another PhD student from our 
laboratory and with the help and supervision of Francesco Saverio Tedesco, 
I have significantly contributed to the develop and improve of the available 
protocols and methodologies utilised to perform the in vivo experiments 
detailed in this thesis. The improvements have been introduced in the 
transplantation protocols, to allow fine tune of the transplantation and 
ameliorate the welfare of the animals utilised for the studies implementing the 
3Rs (reduction, refinement and replacement). 
The techniques utilised in this thesis included surgical procedures and 
cell transplantation in murine models of muscle regeneration and muscular 
dystrophy. These techniques require extensive training and supervision and 
for this reason, we decided to detail these methods in a protocol paper / 
video protocol highlighting the steps required for this approach (Gerli et al., 
2014). This paper details the procedure of intramuscular and intra-arterial 
transplantation of myogenic progenitors, describing the steps required for the 
preparation of cultured cells, the transplantation procedure and possible 
ways to evaluate the functional amelioration of the animal’s phenotype. The 
aim of this paper is not only to provide visual training material for researchers 
that aim to acquire these techniques, but will also help other scientist aiming 




Amongst the various refinement of the protocols achieved along these 
years, recent updates include the use of gas anaesthesia (e.g. isofluorane) 
over the previously utilised injectable tribromethanol (Avertin) (Tedesco et al., 
2011). Although Avertin is easily accessible and simple to administrate via 
intra-peritoneal injection, it’s toxicity and side effects led some countries 
(including the United Kingdom) to ban its use for recovery procedures (Meyer 
and Fish, 2005). Isofluorane gas anaesthesia requires additional equipment 
and training but offers less side effects, lower toxicity and faster recovery, 
significantly improving the animal welfare (Ludders, 1992).  
For intramuscular injection procedures, the volume in which the cells 
are re-suspended has been reduced from 50 µl to 30 µl aiming to reduce the 
volumetric stress to the muscles. On the other hand, a volume of 50 µl has 
been chosen for intra-arterial transplantation, since it has no reported 
influence on the total blood volume of the mice (1.5 - 2.5 ml). This more 
diluted cell suspension keeps the solution less thick, facilitating the flow 
through the small 30 G needle, reducing the stress for the cells and allowing 
a more precise volume dosing. 
Administration of the non-steroidal anti-inflammatory analgesic 
Caprofen, previously performed via subcutaneous injection after the surgery 
has been anticipated on suggestion of the NACWO to 40 minutes before 
starting the procedure. This allows achieving the active analgesic effect 
concomitantly with the beginning of the procedure, further reducing the 
discomfort for the animals. 
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4.2. Derivation of mesoangioblast-like myogenic progenitors 
from pluripotent stem cells. 
 
Cell therapy approaches aiming to treat pathologies that affect large body 
districts such as in the case of muscular dystrophies have to face the 
problem of the limited expansion potential of primary cells. The possibility of 
differentiating myogenic progenitors from pluripotent stem cells might help to 
overcome this limitation. 
In parallel with the main line of research conducted during my PhD, 
starting from the year before registering to the graduate school, I have 
significantly contributed to the development of a method to differentiate 
mesoangioblast-like myogenic cells from human iPS cells (HIDEMs). With 
this newly established protocol we derived HIDEMs from healthy donor and 
patient specific LGMD2D dystrophic iPS cells. We then genetically corrected 
these patient-derived cells with a lentiviral vector containing the gene 
mutated in this pathology (the alpha-sarcoglycan) and successfully engrafted 
these cells in an ad-hoc generated dystrophic immunodeficient murine model 
of the disease. The results obtained were published in Science Translational 
Medicine during the first year of my PhD (Tedesco et al., 2012).  
During the following years I provided equal contribution together with 
Sara Martina Maffioletti (PhD student in our group), in extending the 
applicability of this protocol to human embryonic stem cells and iPSCs 
cultured in feeder-independent conditions. The methodology required to be 
amended in several of the culture step, adjusting seeding density and culture 
conditions to accommodate the different cell mortality and adaptability to the 
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substrate observed in particular for the feeder-independent iPSCs. Once 
adapted, this protocol has been applied to generate new lines of patient 
specific and healthy donor HIDEMs, in light of a collaborative project carried 
out with Sumitava Dastidar, PhD student in Thierry VandenDriessche and 
Marinee K Chuah laboratory at the Free University of Brussels, Belgium. 
With the aim of increasing the accessibility to the method to other 
groups and allow a better reproducibility, a detailed version of the protocol 
including these recent ameliorations, has been included in a recently 
published protocol paper in which I am listed as co-first author (Maffioletti et 
al., 2015). This protocol paper has been also selected as the cover story of 
the journal (Nature Protocols, July 2015, Volume 10 No 7). 
As mentioned above, this methodology allows the production of a 
potentially unlimited amount of cells with a robust myogenic differentiation 
potential (triggered by synchronous activation of MyoD). This opens 
possibilities for further developments not only in the field of cell therapy, but 




CHAPTER 5:  
5. RESULTS: Direct reprogramming of adult muscle 
satellite cells to pericyte-like cells via Notch and 
PDGF signalling 
The main aim of this chapter is to investigate the fate plasticity of adult 
muscle satellite cells, focussing on the possibility to directly reprogram these 
cells towards the pericyte lineage exploiting Notch and PDGF signalling. The 
experimental results reported in this section of the thesis aim to investigate 
this possibility, stimulating these two pathways with DLL4 and PDGF-BB, 
previously reported to exert a similar effect on embryonic myoblasts 
(Cappellari et al., 2013). Treated satellite cells have been evaluated for 
variation in morphology, gene expression pattern and ability to undergo 
myogenic differentiation in vitro. We have then assessed if treated cells 
acquire the pericyte abilities of stabilising endothelial networks and migrate 
through endothelial layers in vitro. To investigate if the cells acquire beneficial 
properties exploitable for cell therapy purposes, such as improved 
engraftment and the ability to cross the blood vessel walls, we report here the 
results of proof of principle transplantation experiments in dystrophic mice. 	 	
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5.1. Primary satellite cells change their morphology when 
subjected to DLL4+PDGF-BB treatment 
 
Primary satellite cell cultures were established from wild type mice and 
cultured on type I collagen-coated dishes in an ad-hoc defined satellite cell 
medium (please refer to the materials and methods section for further details 
on the primary cell isolation and culture). The cells were then seeded on 
DLL4-coated dishes and supplemented daily with PDGF-BB. After one week 
of treatment the cells, that initially showed a circular morphology typical of 
satellite cells, acquired a more flat elongated shape resembling the one of 
cultured control pericytes (Figure 18A). This phenomenon was shown to be 
consistent over three independent cell preparations. Cultured cells have been 
imaged and cell circularity was evaluated using the ImageJ measurement 
tool. Treated cells revealed that a remarkable decrease in the average cell 
circularity ratio indicating the consistent acquisition of a non-circular 




Figure 18. Characterisation of the morphological properties of treated 
satellite cells. A Phase contrast images showing the morphology of 
untreated satellite cells (Left), satellite cells treated with DLL4+PDGF-BB 
(Centre) and pericyte-derived mesoangioblasts (Right; scale bar 80µm). B To 
quantify the variation in morphology, the circularity ratio of the cells has been 
evaluated using ImageJ.  A minimum of 500 cells / condition has been 
measured from three independent experiments. Data are represented as 
mean circularity ratio ± SEM; Satellite cells 0.66 ± 0.01; Treated 0.42 ± 0.01; 
CT Pericytes 0.23 ± 0.003. One-way ANOVA P-value 0.0001  (Pairwise 
comparisons have been performed using the Bonferroni’s method and are 
reported on the graph as:  **** P<0.0001). 
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5.2. Treated cells show increased alkaline phosphatase 
activity 
 
Alkaline phosphatase is a recognised marker of skeletal muscle pericyte-
derived mesoangioblasts (Tonlorenzi et al., 2007). For this reason cells 
subjected to the DLL4 and PDGF-BB stimulation were assessed for the 
presence of alkaline phosphatase enzymatic activity using the NBT/BCIP kit 
(Roche; Please refer to the material and methods section for further details). 
This kit allows the formation of a black/purple precipitate in the cells 
expressing the enzyme (Figure 19A). The treated satellite cell cultures 
showed an increase in the percentage of AP-positive cells compared to the 
untreated population and even higher than the one observed in control 





Figure 19. Evaluation of the Alkaline Phosphatase enzymatic activity in 
treated and control cells. A The panel depicts an overlay of phase contrast 
and Hoechst images of untreated satellite cells, treated satellite cells and 
control pericytes. Alkaline Phosphatase (AP) positive cells are identified by 
the formation of a black precipitate in their cytoplasm (Right; scale bar 90 
µm). B The graph shows the percentage of AP positive cells. A minimum of 
nine 1.5 mm2 microscopic fields has been quantified from three independent 
experiments. The column bars represent the mean percentage of AP positive 
cells / field ± SEM: Satellite cells 1.16 ± 0.14; Treated 10.5 ± 2.53; CT 
Pericytes 3.76 ± 0.50; One-way ANOVA p-value: 0.0008. Pairwise 
comparisons have been performed using the Bonferroni’s method and are 
reported on the graph as: ns not significant; ** P<0.01; *** P<0.001. 
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5.3. DLL4+PDGF-BB treatment induces a reversible 
decrease in cell proliferation 
 
Growth curve proliferation analyses revealed that DLL4+PDGF-BB treated 
satellite cells proliferate less in comparison with both satellite cell-derived 
myoblasts and control pericytes (Figure 20A). Notch signalling is well known 
to control satellite cell activation and quiescence (Brohl et al., 2012; Mourikis 
et al., 2012), therefore the reduction in cell proliferation observed with the 
DLL4 treatment is not surprising. Although this result appears to be in 
contrast with the short-term proliferation analyses performed on embryonic 
myoblasts (Cappellari et al., 2013), experiments on DLL1-mediated Notch 
activation (Parker et al., 2012a; Parker and Tapscott, 2013) and upon 
overexpression of the Notch intracellular domain (Wen et al., 2012) reported a 
similar proliferative slowdown in both canine and murine adult satellite cells. 
Importantly the reduction of proliferation observed did not impede the cell 
expansion required for transplantation purposes.  
This reduction in the proliferative capacity has also been observed 
when the treatment was started on satellite cells that have been already 
cultured for two weeks in control conditions. This indicated that cultured 
satellite cells preserve responsiveness to the treatment at least up to 8 
passages (Figure 20B, red inset). Interestingly, this phenomenon was 
reversible when the treatment was discontinued after two weeks, confirming 
its signal-dependence. Seeding treated cells in un-supplemented satellite 
cells culture condition promptly restored their proliferative potential (Figure 
20B, red inset). 
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Figure 20. Proliferation analysis on DLL4+PDGF-BB treated satellite 
cells. A The graph shows the proliferation curve obtained culturing satellite 
cells, DLL4+PDGF-BB treated satellite cells and control pericytes. The cells 
have been counted every other day for three weeks. Each point represents 
the average counting of three independent experiments. Each point 
represents the average of the counting obtained from three independent 
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experiments; error bars represent the SEM. Statistical significance between 
the Satellite cell and DLL4+PDGF-BB group has been assessed with  Two-
way ANOVA (Bonferroni’s multiple comparison) ** P<0.01; **** P<0.001 B 
The graph shows the same proliferation curve in which an additional set of 
data has been added. Two weeks after having started the treatment or having 
cultured the cells un-supplemented, a fraction of each population was seeded 
in the opposite culture condition and its proliferation was assessed for an 
additional week to verify the reversibility of the treatment and the possibility of 
starting it on long-term cultured cells (red rectangle). Each point represents 
the average of the counting obtained from three independent experiments; 
error bars represent the SEM. Statistical significance between the two groups 
with the switched culture conditions has been assessed with a Two-way 
ANOVA (Bonferroni’s multiple comparison) * P<0.05; ** P<0.01.  Part of these 
proliferation analyses, have been performed under my supervision by James 
Lane and Ekin Ucuncu. 
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5.4. Treated cells show Notch-dependent reduction of their 
myogenic differentiation potential 
  
Notch activation has been widely reported to inhibit myogenesis in embryonic 
and adult myoblasts in vitro (Brohl et al., 2012; Conboy and Rando, 2002; 
Delfini et al., 2000; Mourikis and Tajbakhsh, 2014; Nofziger et al., 1999). To 
assess if this mechanism is also triggered upon the DLL4+PDGF-BB 
treatment, cells were seeded at high density (1.2x104 / cm2) as previously 
reported (Tedesco et al., 2011), grown to confluence and kept for one week in 
myogenic differentiation medium (DMEM supplemented with 2% horse 
serum) as previously described. This myogenic differentiation assay revealed 
that satellite cells previously subjected to the DLL4+PDGF-BB treatment have 
a reduced myogenic differentiation ability compared to both untreated satellite 
cells and control pericytes (Figure 21A, left; Figure 21B, left plot) 
To further investigate the possible Notch dependency of this 
phenomenon, replicate dishes of the differentiating cultures were 
supplemented with a γ-secretase inhibitor (L-685,458). This molecule blocks 
the Notch signalling cascade hampering the proteolytic activation of Notch 
receptor, operated by the γ-secretase, consequently preventing nuclear 
translocation of the Notch intracellular domain (Vilquin et al., 1994). Blocking 
the Notch cascade with the γ-secretase inhibitor treatment was sufficient to 
revert the functional impairment observed in the treated cells and restore the 




 Figure 21. Assessment of myogenic potential of DLL4+PDGF-BB 
treated cells, with and without γ-secretase-mediated Notch signalling 
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inhibition. A Immunofluorescence staining for Myosin Heavy Chain (MyHC; 
marker of terminal myogenic differentiation) performed on untreated satellite 
cells, treated satellite cells and control pericytes subjected to a terminal 
myogenic differentiation assay with and without γ-secretase inhibitor 
supplementation (Scale bar 100µm). B The graph on the left shows 
quantification of the percentage of nuclei inside myosin heavy chain positive 
cells. The plot indicates that cells treated with DLL4+PDGF-BB shows 
reduced myogenic potential in comparison with untreated satellite cells and 
pericyte controls. The data are represented as mean percentage of nuclei 
inside Myosin Heavy Chain positive cells ± SEM: Satellite cells 70.39 ± 2.58; 
Treated 27.64 ± 8.23; CT Pericytes 77.88 ± 2.07; One-way ANOVA p-value 
0.0009. Pairwise comparisons have been performed using the Bonferroni’s 
method and are reported on the graph as: ns not significant; ** P<0.01. A 
minimum of 10 10x (1.5mm2) fields quantified in 3 independent experiments. 
The plot on the right shows the effect of γ-secretase inhibitor supplementation 
in reverting the myogenic inhibition trend as observed in two independent 
experiments. Data are represented as mean percentage of nuclei inside 
Myosin Heavy Chain positive cells ± SEM: Satellite cells 83.90 ± 1.3; Treated 
78.35 ± 1.34; CT Pericytes 96.4 ± 0.94.  
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5.5. Gene expression profile of treated satellite cells  
 
To investigate a possible variation in the gene expression profile of the cells 
upon DLL4+PDGF-BB treatment and understand the reasons for the 
observed proliferation and myogenic potential reduction, a series of 
quantitative real time PCR (qRT-PCR) analyses was performed. After the 
treatment, RNA was extracted and reverse transcribed to cDNA. A first series 
of qRT-PCRs was performed aiming to verify the effect of DLL4 on the cells 
in activating the Notch signalling pathway. Analysis of the expression of its 
target gene Notch1 and of its downstream regulators Hes1 and Hey1 
confirmed that these three genes were upregulated in treated cells (Figure 22 
top row), validating the effectiveness of the treatment. The expression of the 
satellite cell marker Pax7 increased in treated cells (although without 
reaching statistical significance), giving a qualitative indication of an 
increased quiescence status. This hypothesis was confirmed by reduction of 
the MyoD transcript, indicating a less-activated status (i.e. more satellite cell-
like and less myoblast-like). A remarkable increase in the expression of the 
PDGFrβ gene was observed upon treatment (Figure 22 central row). This 
may be because active Notch signalling is reported to be sufficient to induce 
an upregulation of this gene in vascular smooth muscle cells (VSMCs), 
leading also to an increased cell response to PDGF-BB (Jin et al., 2008). 
Further qRT-PCR analyses showed up-regulation of the mostly recognised 
pericyte markers TnAP, NG2, SM22 (Figure 22 lower row) and as mentioned 







Notch1 0,0553923 ns 0,0473 * 1,43E-06 *** 
Hes1 0,0148241 * 0,3383 ns 0,02972 * 
Hey1 0,00909924 * 0,0013 ** 2,56E-13 *** 
Pax7 0,28906 ns 0,5001 ns 0,12335 ns 
MyoD 0,00279303 * 0,0433 * 5,51E-06 *** 
PDGFRb 0,0920756 ns 0,0001 *** 2,00E-16 *** 
TnAP 0,0915078 ns 0,0222 * 1,29E-06 *** 
SM22 0,124432 ns 0,0154 * 2,22E-08 *** 
NG2 0,220125 ns 0,24 ns 0,00575 ** 
 
Figure 22. qRT-PCR analyses on treated and untreated satellite cells. A 
The image shows the calculation of fold increase variation in gene 
expression assessed via qRT-PCR obtained trough the ddCT method. The 
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black bars depict the expression level of untreated satellite cells while the 
white bars depict satellite cells treated with DLL4 and PDGF-BB. Each bar 
represents mean ± SEM of the triplicate qRT-PCR analyses performed for 
three independent biological replicates (3 independent cell preparations 
analysed, each gene analysis run in triplicate). B The table present an 
overview on the statistical analysis performed before the fold transformation 
presented in A. Statistical significance on the dCT has been assessed 
implementing Student’s t-test; Two-way ANOVA and with a multiple 
regression model.  
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5.6. Gene expression profile of treated purified Pax7-nGFP 
satellite cells 
 
To exclude the possibility that the effects observed were artefacts due to a 
possible contamination with other cell types that might be present in the 
primary cell preparations, these analyses were repeated using a purified 
satellite cell preparation. With this aim a collaboration with the group of 
Shahragim Tajbakhsh was established. This group developed in 2009 a 
murine model in which the Pax7 positive cells co-express the nuclear GFP 
(Sambasivan et al., 2009). Thanks to this collaboration, we obtained a 
muscle cell preparation from these Pax7-nGFP mice. Satellite cells were 
then purified from this preparation via fluorescent-activated cell sorting 
(FACS) exploiting their GFP fluorescence (Figure 23A). These cells were 
subsequently treated as described above and used for RNA extraction, 
reverse transcription and qRT-PCR analyses. Purified Pax7-GFP positive 
satellite cells showed a comparable response to the treatment with a gene 




Figure 23. qRT-PCR analyses on treated and untreated purified 
Pax7nGFP positive satellite cells. A Histogram plot of the FACS sorting 
purification of the Pax7nGFP positive cells. In black the profile of a non-GFP 
control satellite cell preparation. The top bar indicates the gate utilised for the 
isolation. B The plots show the fold increase variation in gene expression 
assessed via qRT-PCR. The black bars depict the expression level of 
untreated Pax7nGFP positive satellite cells, while the green bars Pax7nGFP 
positive satellite cells treated with DLL4 and PDGF-BB. Each bar represents 
the average of a triplicate qRT-PCR run performed for each gene. A single 
cell preparation was available for this set of experiments (mice currently not 
available within UCL), therefore the lack of biological replicates impeded the 
assessment of statistical significance. 
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5.7. Reprogrammed cells stabilise endothelial networks in 
vitro 
 
Primary satellite cells were isolated from CAG-EGFP reporter mice. These 
animals ubiquitously express the green fluorescent protein under a strong 
beta-actin promoter (Okabe et al., 1997), thus allowing the isolation of 
fluorescent satellite cells, easily traceable in co-culture experiments. 
Fluorescent satellite cells were then treated as described above (DLL4 
coating and PDGF-BB supplementation), and used for endothelial network 
formation assays (Figure 23A) This assay exploits the property of human 
umbilical vein endothelial cells (HUVECs) in forming vascular-like networks in 
vitro upon vascular-endothelial growth factor (VEGF) stimulation on Matrigel-
coated dishes. In normal conditions, networks formed by the HUVECs are not 
stable and are disrupted in the first twenty-four hours. Among their various 
physiological functions, pericytes contribute to vessel stabilisation. This 
property, previously reported as preserved in vitro, helps the formation and 
stabilisation of HUVEC endothelial networks in vitro (Cappellari et al., 2013; 
Goodwin, 2007; Tedesco et al., 2012; You et al., 2014). We utilised this assay 
to investigate if treated and untreated satellite cells, are capable of behaving 
like bona fide pericytes stabilising endothelial networks in vitro. 
In the first five hours after VEGF stimulation, HUVECs started forming 
the endothelial networks in all of the culture conditions: HUVEC; 
HUVEC+Satellite cells; HUVEC+Treated satellite cells; HUVEC+Control 
Pericytes. Twenty-four hours after the induction, HUVEC networks showed 
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partial disaggregation when cultured alone, they were destabilised when 
HUVECs when co-cultured with control satellite cells but found to be stable 
when HUVECs when co-cultured with satellite cells exposed to DLL4+PDGF-
BB and control pericytes (Figure 24A and B). The number of network 
branches per each 10X microscopic field (1.5 mm2) was quantified and no 
significant differences in its stability were detected at the various time points 
(Figure 24C; average number of branches / 1.5 mm2 ± SEM: HUVEC only 
4.75 ± 1.55; HUVEC+Satellite cells 0.00; HUVEC+Treated 24.25 ± 3.57; 
HUVEC+Treated 48h 19.17 ± 2.15; HUVEC+Treated 72h 23.00 ± 2.48; 
HUVEC+Treated 120h 20.6 ± 3.51; HUVEC+CT Pericytes 42.07 ± 2.26). In 
support to these results, treated satellite cells were found to be in close 
proximity to the HUVEC endothelial networks and were able to stabilise the 
structure for up to 120 hours after induction, consistent with what was 
observed with control pericytes (Figure 24D; number GFP positive cells co-
localised with the network branches / 1.5 mm2 ± SEM: HUVEC only 0; 
HUVEC+Satellite cells 0; HUVEC+Treated 96.99 ± 1.48; HUVEC+Treated 
48h 97.51 ± 1.06; HUVEC+Treated 72h 100.00 ± 0.00; HUVEC+Treated 
120h 99.13 ± 0.54; HUVEC+CT Pericytes 99.14 ± 0.39). 
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Figure 24. Endothelial network formation assay. A Images acquired 
twenty-four hours after the endothelial network induction. HUVECs have been 
utilised as a positive control for the formation of the network (top left). When 
mixed with untreated satellite cells, HUVEC formed an unstable endothelial 
network that dissociated in the first 24 hours while it was stabilised with 
primary pericytes, the positive control of the experiment (Scale bar 100 µm). 
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B The images show that treated satellite cells contribute to the stability of the 
endothelial networks after 24 and 72 hours similarly with what observed with 
control pericytes in A. C The bars represent the quantification of the number 
of GFP positive endothelial networks branches ± SEM. D The bars represent 
the quantification of the average number of GFP positive cells that co-
localised with an endothelial network branch in three independent 
experiments ± SEM. One-way ANOVA (Bonferroni’s multiple comparisons 




5.8. Assessment of migration ability in vitro 
 
The above experiments demonstrated that treated satellite cells acquire 
pericyte markers and network stabilisation properties. A transwell migration 
assay was performed with the aim of investigating if this switch towards the 
pericyte lineage was reflected also in increased migration ability. Treated and 
untreated GFP-positive satellite cells were seeded on a murine H5V 
endothelial layer previously grown on an 8 mm-pored transwell membrane 
coated with 1% gelatine. The upper chamber of the well was loaded with 
serum-deprived medium while the lower chamber of the transwell was loaded 
with myotube-conditioned medium to give the cells a chemoattractant 
stimulus to migrate through the endothelial layer (Figure 25A). The number of 
GFP-positive cells that migrated through the endothelial layer over 6 hours 
was calculated to be for the treated cells 2.4 folds more than the untreated 
control, indicating that treated cells have an improved migration ability, either 
superior to the one observed with control pericytes (Figure 25B; number of 
GFP-positive cells / 1.5mm2 microscopic field ± SEM: H5V+Satellite cells 
45.13 ± 1.83; H5V+Treated 113.7 ± 5.27; H5V+CT Pericytes 85.91 ± 1.89; 
H5V 0).  
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Figure 25. Assessment of cell migration through a layer of endothelial 
cells. A The panel shows images of the lower side of the transwell 
membranes utilised to assess the migration of treated and untreated GFP-
positive satellite cells. The top part of the panel shows merged phase contrast 
and green fluorescence images of the lower side of the transwell membranes 
at a 6-hour time point. The non-fluorescent cells are murine endothelial H5V 
cells, which migrate freely through the pored membrane. The bottom images 
depicts the green fluorescent channel of the same fields, in which GFP-
positive cells are those that migrated through the endothelial layer (Scale bar: 
100 µm) B The bar graph depicts the quantification of the GFP-positive cells 
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that migrated through the membrane in 2 independent experiments performed 
in triplicate, in which a minimum of 15 1.5mm2 microscopic field / condition 
were quantified. These data represent the outcome of 2 independent 
biological experiments; a third independent biological replicate will be 
performed within the project of Ekin Ucuncu, MRes student in the laboratory. 
The final results of this experiment will be then included in a manuscript 
describing this project currently under preparation. 		 	
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5.9. Treated cells show no evidence of tumourigenesis 
 
 One of the strengths of the above-described DLL4+PDFG-BB direct 
reprogramming approach resides in the lack of genetic manipulation. 
Compared to other gene-based reprogramming strategies, the methodology 
developed in this thesis aims to obtain a cell product with less safety hurdles. 
To confirm that the signalling manipulation did not induce cell transformation, 
tumour formation assay were performed injecting treated and untreated 
satellite cells subcutaneously in immune-deficient (scid/beige) mice (please 
refer to the material and methods section for further details). None of the 
animals that received the injections showed the presence of a tumour mass 
after 2 months of follow up (n = 5), providing preliminary indication of the 
safety of the strategy. 
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5.10. Increased engraftment in dystrophic animals upon 
intramuscular delivery  
 
To assess whether the treatment with DLL4+PDGF-BB has a positive impact 
on myoblast engraftment potential a pilot intramuscular transplantation 
experiment was performed. Treated and untreated satellite cells were 
transduced with a nuclear LacZ lentiviral vector; this approach was then 
utilised to allow the detection of the donor-derived nuclei via X-Gal staining in 
an intraspecific mouse-into-mouse transplant. In this experiment 5 x 105 cells 
were intramuscularly transplanted in two dystrophic immunodeficient α-
sarcoglycan-null/Scid/Beige mice. Three weeks after transplantation, the 
animals were humanely culled and the transplanted muscles explanted. X-Gal 
and α-sarcoglycan staining were performed on cryosections of the 
transplanted muscles to evaluate cell engraftment and differentiation (Figure 
26A). We observed an increase in the average number of X-Gal positive 
nuclei in the sections of the muscles transplanted with the DLL4+PDGF-BB 
treated cells, in comparison to the ones transplanted with untreated satellite 
cells (Figure 25B; 44 sections analysed, average number of Xgal positive 
cells / section ± SEM: Satellite cells 10.51 ± 1.74; DLL4+PDGF-BB 110.3 ± 
8.08). Similarly, an increase in the number of donor derived α-sarcoglycan 
positive myofibres (completely absent in this murine model) was observed 
(Figure 25C; 24 sections analysed, average number of αSG positive fibres / 
section ± SEM: Satellite cells 3.58 ± 0.67; DLL4+PDGF-BB 36.96 ± 3.73). 
This data is purely qualitative considering the small sample size (n = 2) and 
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further biological replicates will be required to assess statistical significance 
and validate these preliminary encouraging results. 
 
 
Figure 26. Intramuscular transplantation of reprogrammed satellite cells. 
A The panel shows on the left X-Gal staining to assess the presence of 
nLacZ positive donor derived cells. The central column depicts an overlay of 
the X-gal staining, with immunofluorescence staining to detect the presence 
of the α-sarcoglycan (Sgca), also depicted on the right as an overlay with the 
nuclear dye Hoechst (Scale bar: 180µm). B The graph on the left depicts the 
average number of nLacZ positive nuclei traced in each 7µm-thick muscle 
section analysed ± SEM (44 sections analysed). The graph on the right 
depicts the quantification of the average number of α-sarcoglycan positive 




5.11. Treated satellite cells acquire the ability to cross the 
vessel wall upon intra-arterial delivery 
 
As an additional proof of principle experiment, we transplanted 2.5 x 105 cells 
in the femoral arteries of two Sgca-null/Scid/Bg mice as previously detailed 
(Gerli et al., 2014). Two weeks after transplantation the presence of donor-
derived nLacZ positive nuclei in the muscles downstream of the injection site 
was assessed via whole mount X-gal staining of the hind limbs. The 
presence of donor-derived nuclei was scarce in the animals transplanted with 
control satellite cells, with a total of 2 nuclei identified by stereoscopic 
microscopy (Figure 27A top row). Animals transplanted with treated satellite 
cells instead showed a more marked presence of donor cells at two weeks 
post-transplantation, with up to 53 nuclei identified (Figure 27A bottom row). 
Donor-derived myonuclei were identified upon X-Gal and eosin stainings on 
sections from muscles transplanted with treated satellite cells, indicating 
fusion of donor nuclei with the host myofibres (Figure 27B). 
Immunohistochemistry staining performed on the sections showed that the 
positive nuclei did not co-localise with PECAM-positive vessels (in brown; 
Figure 27C), indicating that treated cells has the ability to cross the blood 
vessel wall upon systemic delivery. Further experiments will be performed 
prior to submission of this project for publication, in order to quantitatively 




Figure 27. Evidence of in vivo migration of DLL4+PDGF-BB treated cells 
engrafted upon intra-arterial delivery. A Stereomicroscopic images of 
murine limbs that received untreated (top) and treated satellite cells (bottom). 
Donor-derived nuclei are labelled in blue upon whole mount X-gal staining 
giving preliminary indications of engraftment upon intra-arterial delivery 
(Scale bars: Left 1mm; Right 0.5mm). B The panel shows phase contrast 
images of sections of the muscles explanted from animals that received intra-
arterial delivery of untreated (top) and treated satellite cells (bottom). The left 
images depict haematoxylin and eosin staining showing the presence of blue 
nuclei within the muscle fibres. On the right, immunohistochemistry staining 
for the endothelial marker PECAM (right) performed on the serial sections 
highlight the localisation of the donor-derived X-Gal-positive nuclei outside 
the PECAM positive vessel structures (Scale bar: 100 µm).		 	
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5.12. Conclusions 	
The results reported in this chapter indicate that adult muscle satellite cells 
respond to a treatment with the Notch ligand DLL4 in combination with the 
growth factor PDGF-BB, acquiring a pericyte/mesoangioblast-like phenotype. 
The treatment induced a morphological switch from the classic round shape 
typical of satellite cells, to a more elongated morphology that resembles the 
one of fibroblasts / pericytes (Figure 18). An increase in the alkaline 
phosphatase enzymatic activity provided indication of a possible shift towards 
the pericyte lineage (Figure 19). This hypothesis was then verified via qRT-
PCR analysis, showing an increased level of expression of all the pericyte 
markers analysed (TnAP, NG2, SM22, PDGFrβ; Figure 22 and 23).  
The effectiveness of the Notch stimulation was also confirmed upon 
qRT-PCR analyses. The increased expression of Notch1 and its downstream 
targets Hes1 and Hey1, confirmed the presence in treated cells, of an active 
Notch signalling cascade (Figure 22 and 23). This activation led also to a 
Notch-dependent reduction in the myogenic potential of the cells. This 
phenomenon resulted to be fully reversible upon blocking of the Notch 
signalling cascade with a γ-secretase inhibitor (Figure 21). 
Surprisingly, in contrast with our fate switch hypothesis, we observed 
an up-regulation of the satellite cell marker Pax7 indicating that upon 
treatment, the cells maintained a “satellite cell memory”. This Pax7 up-
regulation, in combination with a down regulation of the activation marker 
MyoD, appears to recapitulate what is considered a “quiescence profile” 
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(Figure 22 and 23). In line with this possible “increased quiescence”, treated 
cells showed reduction in their proliferative ability (Figure 20A). This result is 
consistent with what previously reported in other studies involving Notch up-
regulation in myogenic progenitors (Parker et al., 2012a; Quattrocelli et al., 
2014; Wen et al., 2012). Interestingly we confirmed the signalling-
dependence of this phenomenon easily reverting the reduced proliferation 
trend by discontinuing the treatment (Figure 20B).	
Treated cells resulted capable in stabilising endothelial networks in 
vitro upon co-culture with primary endothelial cells (Figure 24). This assay 
models in vitro the ability of pericytes to contribute to vessel stabilisation and 
regulation (Andreeva et al., 1998). The localisation of the cells in proximity to 
the network branches indicated also the role of a physical interaction 
between the two cell types, resembling what happens during Notch/PDGF-
mediated pericyte recruitment operated physiologically by the endothelial 
cells (Armulik et al., 2005; von Tell et al., 2006). Overall these experiments 
provided indication that upon treatment, satellite cells acquire functional 
pericyte properties in vitro. 
Consistently with previous and recent observations on Notch-
stimulated satellite cells and mesoangioblasts (Parker et al., 2012a; 
Quattrocelli et al., 2014), treated cells showed improved engraftment in our 
pilot transplantation experiments in dystrophic mice (Figure 26). Moreover, 
manipulating the Notch and PDGF-BB signalling cascades did not alter the 
safety of the cells upon tumor formation assays. 
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The ability of pericytes / mesoangioblasts to cross the vessel wall 
made this cell type appealing for the development of the cell therapy protocol 
recently exploited in a phase I/II clinical trial (EudraCT no. 2011-000176-33). 
Treated satellite cells showed in vitro ability to migrate through artificial 
endothelial layers superior to the untreated controls and surprisingly even to 
the one observed in control pericytes (Figure 25). Following this path we 
performed a proof-of-principle intra-arterial transplantation experiment in a 
murine model of muscular dystrophy. Three weeks after intra-arterial delivery 
of treated satellite cells, it was possible to identify donor-derived cells outside 
the PECAM-positive vessels and inside the host myofibres. This provided 
preliminarily indication on the possibility of delivering manipulated satellite 
cells/myoblasts through the arterial circulation (Figure 27). 
In conclusion these results show for the first time that a DLL4+PDGF-
BB treatment in adult muscle satellite cells induces a partial fate-switch 
towards the pericyte lineage. This triggers the acquisition of a hybrid pericyte / 
satellite cell phenotype that gives to the cells possible beneficial properties for 
cell therapy. Although further in vivo validation of this strategy will be required, 
the results obtained so far indicate that treated satellite cells acquire pericyte 
features and show an increased engraftment potential (Figures 26 and 27). 
Importantly, these reprogrammed cells acquired improved migration and 
extravasation properties superior to what observed with untreated satellite 
cells. Overall this project highlights that a satellite cell / pericyte conversion 
could be considered a new and exciting strategy to develop novel cell therapy 
strategies for muscle diseases.  
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CHAPTER 6:  
6. RESULTS: Investigation of self-renewal of pericyte 
/ mesoangioblast derived myogenic progenitors 	
This chapter describes the result achieved in a set of analyses 
complementary to the study on fate plasticity outlined in Chapter 5.  The 
experiments shown above provide evidence of inducible lineage plasticity, 
where satellite cells are reprogrammed to pericyte-like cells. After having 
defined the differentiation capacity of a putative stem/progenitor cell 
population, it is critical to investigate its self-renewal potential. While it is 
reported that satellite cells can self-renew in vivo, even upon serial 
transplantation (Rocheteau et al., 2012) it is not known if 
pericytes/mesoangioblasts could do the same. Pericytes and 
mesoangioblasts have been shown to contribute to the satellite cell pool upon 
transplantation (Dellavalle et al., 2011; Diaz-Manera et al., 2010; Tedesco et 
al., 2011). The set of experiments detailed in this chapter was mainly 
performed to investigate the self-renewal potential of mesoangioblast-derived 




6.1. Wild type mesoangioblasts engraft host dystrophic 
skeletal muscles and generate clonogenic SM/C-2.6 
positive and negative cells 
A first series of transplantation experiments has been conducted using 
previously characterised wild type adult mesoangioblasts (C57-MABs; Diaz-
Manera et al., 2010) as a proof-of-principle of the feasibility of the strategy. 
These cells were previously transduced with a lentiviral vector encoding for 
the GFP (driven by a constitutive PGK promoter) in order to trace them in the 
host muscle (Figure 28A). Scid/mdx mice were used as recipient animals for 
these experiments. The Scid/mdx is an immune-deficient model of DMD that 
allows transplant of non-syngeneic cells (Farini et al., 2007). C57-GFP MABs 
were transplanted intramuscularly (106 cells / injection) into tibialis anterior, 
gastrocnemius and quadriceps muscles of scid/mdx mice (n=4). One month 
after transplantation, the muscles were explanted and analysed under a 
fluorescent stereomicroscope to confirm the presence of GFP-positive areas 
(Figure 28B). The samples were then digested mechanically and 
enzymatically with the aim of isolating mononuclear cells. The cell suspension 
obtained with the digestion was then FACS-purified to retrieve donor-derived 
GFP positive and SM/C-2.6 positive (13.9%; 1.4 x 105 cells) and donor-
derived GFP positive and SM/C-2.6 negative cells (0.13%; 1.3 x 103 cells) 
(Figure 28C). SM/C-2.6 is a monoclonal antibody reported to allow the 
separation of satellite and non-satellite cells (Fukada et al., 2004). Previous 
experiments performed in our laboratory confirmed the identity of the cells 
isolated with this method through immunofluorescence staining for the 
satellite cell marker Pax7 (Tedesco et al., 2011; Figure 4J).  
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The clonogenic assay is a well-established method for testing survival 
and proliferative capability of cells. The ability to form single cell clones is a 
shared property of both satellite cells and mesoangioblasts (Dellavalle et al., 
2007; Molnar et al., 1996; Zammit et al., 2006a). For this reason the two 
donor derived cell fractions were subjected to single cell cloning and showed 
respectively a 20.1% and 68% ability of generating single cell clones (29/144 
and 98/144 of the single cells seeded generated a clonal colony).  
Experimental replicates of the transplanted muscles have been also 
analysed via cryosectioning and immunofluorescence, to confirm the 
presence of GFP co-localised with donor derived dystrophin positive 
myofibres (Figure 28D). Two randomly picked clones were subsequently 
expanded in culture, assessed for myogenic differentiation in vitro and 
transplanted with the same setup utilised for the polyclonal population. After 
one month, the muscles were explanted and processed for imaging as 
described above (representative example in Figure 28E). The results with this 
experiment have indicated the feasibility of the serial transplantation approach 
and have provided preliminary indication that the regenerative potential of 
donor mesoangioblasts is retained also at the clonal level.  
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Figure 28. Serial transplantation of wild type mesoangioblasts in 
dystrophic mice. A Fluorescent microscopy image of the c57-GFP MABs 
utilised for this set of experiments (Scale bar: 50um). B Stereomicroscopic 
image showing the green area, engrafted by GFP-positive cells, in a tibialis 
anterior muscle explanted one month after transplantation (Scale bar: 0.5mm). 
C Dot plot of the FACS sorting performed on the digested muscles aiming to 
isolate the GFP and SM/C-2.6 fractions. D Section of a transplanted muscle 
showing the engrafted GFP positive area. This area co-localises with 
dystrophin-positive fibres traced via immunofluorescence (centre) and 
quantified on the plot on the right (Scale bar: 100µm) E The images show a 
muscle transplanted with a GFP positive SM/C2.6 positive clone. Sections of 
the muscles highlight co-localised positivity for GFP (central) and dystrophin 
(right) indicating the donor origin of the fibres (Scale bar: 0.5mm and 100µm). 
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This last part of the panel is part of the characterisation work currently on 




6.2. Dystrophic mesoangioblasts, genetically corrected with 
a human artificial chromosome, are serially 
transplantable 	
On the basis of the experiments with wild type mesoangioblasts, a second 
series of serial transplants utilising genetically corrected cells was performed. 
These cells, namely DYS-HAC mesoangioblasts, were previously generated 
from dystrophic mdx mesoangioblasts genetically corrected with a human 
artificial chromosome (HAC) containing the entire human dystrophin locus 
(Tedesco et al., 2011). EGFP was also included in the HAC as fluorescent 
marker to allow cell tracing in transplantation setups. These cells have been 
previously shown capable of long-term engraftment (8 months), generated 
Pax7 positive satellite cells and sustained muscle regeneration after acute 
injury of the transplanted muscles (Tedesco et al., 2011). Here we sought to 
formally assess the self-renewal capacity of these mesoangioblast-derived 
cells in a serial transplantation approach (For a schematic overview on the 
experiment see Figure 29A).  
Transplantation of mesoangioblasts containing the DYS-HAC was 
performed in mdx/scid mice as described above. At variance with the 
experiments performed with wild type mesoangioblasts, in this series of 
transplants we administered 3 x 106 cells / muscle, aiming to increase the 
number of isolated cells, to reduce the culture time required to obtain 
sufficient cells for the following transplantation. One month after the injection, 
the transplanted muscles were mechanically and enzymatically digested. The 
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derived cell suspension was FACS purified for EGFP and SM/C-2.6. Both 
SM/C-2.6 positive and negative fractions have been isolated, cultured and 
cryopreserved for future analyses. We then serially transplanted only the 
SM/C-2.6 positive donor derived fraction, assuming that this contained mostly 
satellite cell. The SM/C-2.6 negative population was harvested, cultured and 
cryopreserved for future analyses. The donor derived SM/C-2.6 positive cells 
were cultured and assayed for their myogenic potential in vitro. After one 
week in myogenic differentiation medium, cells generated large 
multinucleated myotubes positive for myosin heavy chain and human 
dystrophin (Figure 29B), indicating that a subpopulation of transplanted cells 
did not fuse with the host myofibres, maintaining an undifferentiated 
mononuclear state in vivo that allowed re-isolation. The transplanted muscles 
utilised to re-isolate the cells have been assessed for engraftment by 
stereomicroscopic fluorescence. This assay revealed the presence of EGFP 
positive areas in the transplanted muscles indicating the contribution of donor 
cells to the muscle regeneration (Figure 29C). As an additional confirmation 
of engraftment, a series of transplanted muscles was processed and cryo-
sectioned in order to perform immunofluorescence staining to assess the 





Figure 29. Serial transplantation of genetically corrected DYS-HAC 
mesoangioblasts in scid / mdx mice. A Experimental scheme of the serial 
transplantation of genetically-corrected DYS-HAC mesoangioblast-derived 
cells (Illustrations obtained from Servier Medical Art). B Immunofluorescence 
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staining of in vitro differentiated donor-derived Sm/c-2.6-positive cells 
isolated in light of this project. The cells show the expression of EGFP, 
myosin heavy chain (MyHC) and dystrophin (scale bars 120 µm). C 
Representative stereomicroscopic images showing bright field (top) and 
EGFP-positive area (bottom) of a gastrocnemius muscle explanted after the 
second round of transplant (scale bar 0.5 mm). D Cryostat section and 
immunofluorescent staining of the same muscle shows the expression of 
dystrophin co-localised with the EGFP engrafted area of a serial section 
(scale bar  100mm). E An example of a FACS-sorting dot plot obtained after 
digestion of replicates of the muscle shown in (C). The isolated double-
positive cells are shown in the bottom part of the panel, both in phase 
contrast and by direct fluorescence (scale bar 120 µm). 
The SM/C-2.6 positive cells were also expanded in culture and serially 
transplanted intramuscularly in scid/mdx mice (n = 6). One month after the 
second round of transplantation, muscles were harvested. Some of the 
explanted muscles were included for histological analysis; the remainder were 
digested and isolated cells were FACS-sorted as described above. EGFP-
positive areas visible upon analysis using the stereomicroscope suggested 
successful engraftment of donor cells in host muscles (Figure 30A). EGFP-
positive and SM/C-2.6-positive cells were again cultured and used for a third 
round of serial transplantation in scid/mdx mice (n = 6), scaling down the cell 
number to 2 x 106 cells / muscle. One month later, transplanted muscles were 
harvested, digested and FACS-sorted as described above (Figure 30B). Both 
the EGFP-positive / SM/C-2.6-positive and the EGFP-positive / SM/C-2.6-
negative fractions were collected and amplified. We then performed a single 
cell cloning experiment with the aim of investigating if cells undergoing 3 
rounds of serial transplantation retained their clonogenic ability. Both 
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populations generated single cell clones to a different extent (SM/C-2.6-
positive: 23.61%, SM/C-2.6-negative: 65.6%). Interestingly, two clones (A9 
and B5), obtained from the double positive fraction were expanded and 
transplanted into scid/mdx mice, scaling down the dose to 106 cells / muscle 
(n = 4 / clone) (Figure 30C). Characterisation of the cryosectioned replicates 
from transplanted muscles and of the SM/C-2.6-negative fractions is on going 
as part of the project of Chrystalla Constantinou, an UCL MRes student that I 
am co-supervising, currently working in the laboratory. Overall these results 
indicate that genetically corrected mesoangioblast-derived satellite cells can 
support three rounds of serial transplantation, plus an additional one as single 
cell clones. Both SM/C-2.6 positive and negative (satellite-like and non-
satellite-like) cells were generated at every step, providing indications on the 
ability of these cells to self-renew. 
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Figure 30. Engraftment and isolation of DYS-HAC mesoangioblast-
derived cells upon further rounds of serial transplantation. A 
Stereomicroscopic image of a transplanted muscle at the 2nd round of 
transplantation, with the paired FACS sorting plot (Scale bar: 0.7 mm). B 
Stereomicroscopic image of a transplanted muscle at the 3nd round of 
transplantation, with the paired FACS sorting plot (Scale bar: 0.7 mm). C 
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Stereomicroscopic image of two muscles that have been transplanted with 
cells expanded from single cell clones obtained with the sorting in B (Scale 
bar: 0.7 mm). 
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6.3. Fresh isolation of primary pericytes for serial 
transplantation 
To further test the hypothesis that pericytes are able to generate self-
renewing cells in vivo, a series of experiments combining serial 
transplantation and lineage tracing experiments was recently established. 
Transplanting freshly isolated cells, we aim to eliminate the possible cell 
culture bias. Moreover, under physiological conditions, the number of resident 
myogenic progenitor is not as abundant as in a transplantation setup. For this 
reason, we decided to reduce the number of transplanted cells (down to 104 
cells / injection). Compared to the experiments based on cultured 
mesoangioblasts shown above, this fresh-isolation strategy aims to get closer 
to the natural process of muscle regeneration.  
The isolation of primary pericytes from freshly explanted tissues was 
performed using the tissue non-specific alkaline phosphatase (TnAP)-
CreERT2 mouse model (Dellavalle et al., 2011). In these animals the Cre 
recombinase is specifically expressed only in TnAP positive cells upon 
exposure to tamoxifen. To perform this series of experiments the TnAP-
CreERT2 mice were crossed with a reporter mouse that carries a floxed 
fluorescent YFP cassette (Srinivas et al., 2001). Subcutaneous injection of 
the oestrogen receptor ligand Tamoxifen in juvenile mice activates the 
recombination and permanently label the TnAP positive cells with the YFP 
fluorescent marker as previously described (Dellavalle et al., 2011). The 
timeline of the administrations detailed in Figure 31A. Isolation of YFP-
positive pericytes was performed using a FACS sorter; isolated cells were 
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viable and positivity for the YFP was confirmed by immunofluorescent 
staining (Figure 31B). 
Transplantation of 104 cells was performed in scid/mdx mice as 
outlined in the schematic representation in Figure 31C. One month after 
transplantation it was possible to isolate YFP-positive, SM/C-2.6-positive cells 
(representative sorting dot plot in Figure 31C. This confirmed that primary 
pericytes give origin to satellite-like cells in vivo, consistently with the data 
obtained in MAB cell lines.  
A reported drawback of the YFP reporter is its faint brightness(Shaner 
et al., 2005). For this reason, together with the lower number of injected cells, 
made the identification of donor-derived cells within the transplanted muscles 
challenging (Figure 31D). However, the number of dystrophin-positive fibres 
in two transplanted tibialis anterior muscles was counted and found increased 
when compared to age-matched non-transplanted controls (Figure 31D, right; 
average number of dystrophin-positive fibres / section ± SEM: transplanted 
55.43 ± 5.186; control 27.55 ± 2.38; 2 animals transplanted and analysed). 
Having age-matched controls (either littermates or an un-transplanted PBS 
injected contralateral muscle from the same animals) is relevant when 
working with scid/mdx mice. In this murine model, some muscle fibres 
undergo a spontaneous exon-skipping event that allows sporadic expression 
of a truncated form of dystrophin on the myofibres’ sarcolemma. These 
myofibres, known as revertant fibres, create a “background noise" that might 
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be problematic in transplantation studies (Pigozzo et al., 2013), in particular 
when the number of transplanted cells is very limited as in this experiment. 
 
Figure 31. Fresh isolation and transplantation of primary pericytes. A 
Tg:TNAP-CreERT2 mice were crossed with R26R-YFP reporters (top), 
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Tamoxifen-induced Cre-Lox recombination was induced following the 
depicted timeline (bottom) and utilised to isolate primary pericyte. The right 
part of the panel depicts a representative sorting plot to isolate primary YFP-
positive pericytes. B Phase contrast and immunofluorescence image of 
freshly-isolated YFP-positive pericytes obtained from the progeny of the 
crossing shown in A (scale bar 100 µm). C Schematic representation of the 
transplantation experiment performed using freshly-isolated pericytes. The 
right part of the panel shows the FACS-sorting dot plot of the cells obtained 
from the transplanted muscles. SM/C-2.6 positive satellite-like cells are 
labelled with an APC fluorochrome. D Immunofluorescence staining showing 
dystrophin and YFP expression on a section of muscle transplanted with 
TNAP-YFP pericytes (scale bar 100 µm). The graph on the right shows 
quantification of the number of dystrophin-positive fibres compared with the 
ones present in an age-matched untransplanted control, aiming to quantify 
the difference in comparison with the baseline number of revertant fibres 





The serial transplantation experiments detailed in this chapter were designed 
to test the self-renewal potential of mesoangioblast-derived cells (presumably, 
donor-derived satellite-like cells). Wild type mesoangioblasts successfully 
engrafted the transplanted muscles giving rise to dystrophin positive fibres. 
These cells were able to generate in vivo SM/C-2.6 positive satellite-like cells 
(Figure 28A-D), which were able to generate single cell clones, capable to re-
engraft dystrophic muscles also upon clonal expansion. This set of data 
provided indications on the self-renewal potential of mesoangioblasts in vivo 
(Figure E).  
A more extensive series of serial transplantation experiments was 
performed using genetically corrected mesoangioblasts containing the DYS-
HAC. These cells already showed a remarkable engraftment potential, the 
ability to regenerate the engrafted tissue upon serial injury and to contribute 
to the satellite cell niche (Tedesco et al., 2011). We report here the ability of 
these mesoangioblast-derived satellite-like cells to serially engraft the 
dystrophic muscles. These cells successfully supported three subsequent 
round of transplantation and re-isolation, generating at each round both 
donor-derived SM/C-2.6 positive and negative cells (Figure 29 and 30). Both 
fractions successfully generated single cell clones after three rounds of serial 
transplantation, indicating that the engraftment in vivo did not impair their 
clonogenic potential. Two randomly picked clones have also been expanded 
and transplanted. These cells engrafted the host muscles indicating their 
preserved myogenic potential (Figure 30C).  
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Overall these data indicate that mesoangioblast-derived satellite-like 
cells are capable of self-renewal upon serial transplantation. It is important to 
mention that due to the articulate process of chromosome transfer requiring 
long term culture and single cell cloning, the DYS-HAC mesoangioblasts have 
lost their spontaneous myogenic potential. For this reason, the starting cells 
have been previously transduced with a lentiviral vector containing MyoD as 
reported in Tedesco et al. (2011). Despite the constitutive expression of 
MyoD, we were able to isolate SM/C-2.6 positive and negative DYS-HAC 
mesoangioblasts-derived mononuclear cells at each round of transplantation. 
This indicates that a fraction of the donor-derived cells did not fuse with the 
host myofibres upon transplantation, acting as a progenitor-reservoir available 
for further rounds of regeneration despite the expression of a factor normally 
associated with commitment more than with self-renewal. This last 
observation is in line with what was published by Zammit and co-workers on 
the dynamics of the endogenous MyoD expression in primary mouse satellite 
cells (Zammit et al., 2004). 
The preliminary results obtained with fresh isolation of TnAP-positive 
pericytes indicate that a serial transplantation approach could be used to 
investigate the self-renewal potential of these cells. However, indications 
obtained with the pilot experiment of transplantation / isolation of YFP cells 
suggested the use of a brighter fluorescent marker will be required to perform 




CHAPTER 7:  
7. Discussion 	
The data reported in this thesis aim to improve our understanding of 
myogenic progenitor biology, particularly focusing on muscle satellite cells 
and pericyte-derived mesoangioblasts, with the aim of developing efficacious 
and long-lasting cell therapy protocols to treat muscular dystrophies. A first 
phase of this project has been dedicated to establishing and optimising the 
available techniques to deliver cells via local intramuscular injection and 
through the vascular route of dystrophic mice. These improvements, detailed 
in chapter 4.1, allowed me to perform the in vivo experiments detailed in 
chapter 5 and 6.  
The results reported in chapter 5 indicate that adult murine satellite 
cells can be conditionally reprogrammed to a pericyte-like fate, upon 
exposure to a combination of the Notch ligand DLL4 and the growth factor 
PDGF-BB. A similar approach, recently described by Cappellari and 
colleagues, demonstrated the acquisition of a pericyte-like phenotype by 
embryonic myoblasts (Cappellari et al., 2013). To our knowledge, this work 
represent the first report indicating that adult satellite cells retain a similar 
level of plasticity. 
With this innovative approach we aimed to make the first steps to 
overtake the major hurdle faced in the development of cell therapy protocols 
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based on satellite cells / myoblasts. Although myoblasts are relatively easy to 
isolate and possess a remarkable myogenic potential, their limited migration 
ability compromised the results achieved in cell therapy protocols based on 
this cell type (Sampaolesi et al., 2003). Having cells with a strong migration 
potential is a crucial requirement to treat large muscular districts affected by 
pathologies like muscular dystrophies (Benedetti et al., 2013; Tedesco and 
Cossu, 2012). Pericyte-derived mesoangioblasts on the other hand, have 
been shown to contribute to muscle regeneration in different animal models 
of muscular dystrophy (Dellavalle et al., 2007; Diaz-Manera et al., 2010; 
Galvez et al., 2006; Gargioli et al., 2008; Giannotta et al., 2014; Sampaolesi 
et al., 2006; Sampaolesi et al., 2003) and are now undergoing clinical 
experimentation with a Phase I/II clinical trial (EudraCT no. 2011-000176-33). 
Our results highlight that adult satellite cells treated with DLL4 and 
PDGF-BB show an increased pericyte marker expression (TnAP, NG2, 
SM22, PDGFrβ), indicating that the level of plasticity so far observed only in 
embryonic myoblasts may be conserved in adulthood. Active Notch signalling 
was confirmed by the increased expression of Notch1 and its downstream 
targets Hes1 and Hey1, indicating the effectiveness of the treatment. The up-
regulation of the PDGF receptors is a known phenomenon in cells with an 
active Notch signalling cascade (Jin et al., 2008). Our strategy might then 
activate a loop leading, through Notch stimulation, to an increased cell 
response to PDGF supplementation.  
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The gene expression analyses conducted by qRT-PCR (Figure 21 and 
22) have been recently extended to a high-throughput gene expression 
profiling using RNA microarrays (Affymetrix GeneChip® Mouse Genome 
430). This set of experiments, performed in collaboration with the team of 
Professor Enrico Tagliafico (Università di Modena e Reggio Emilia, Italy), aim 
to study the clustering of the treated cells in comparison with control 
untreated satellite cells and with control pericytes in a principal component 
analysis. Moreover, these on-going analyses will be extended to other 
muscle cell types, utilising dataset available in the literature (i.e. meta-
analyses). Different sets of genes will then be analysed paying particular 
attention to molecules involved in cell migration, relevant signalling pathways, 
myogenic differentiation genes and other mesodermal progenitor markers. 
Novel potential pericyte marker genes, recently identified in a project 
currently on-going in the laboratory of Professor Giulio Cossu at the 
University of Manchester, will be also assessed for possible up-regulation 
(Moreno-Fortuny A. and Cossu G., unpublished results). The datasets 
generated in light of this collaboration will be also uploaded on the GEO 
repository to make it freely accessible to other researchers in the field. The 
results of these gene expression-profiling experiments will help to unravel the 
molecular mechanism of the fate switch observed in this project. 
Several reports available in the literature have shown that 
transplanted freshly isolated cells (Montarras et al., 2005), myofibres (Collins 
et al., 2005) and even whole muscle biopsies (Zhang et al., 2014), have a 
superior engraftment ability when compared to cultured cells, mainly because 
	 170	
a more quiescent status (and/or the niche)  is preserved. Our results suggest 
that, at variance with their embryonic counterpart (Cappellari et al., 2013), 
adult satellite cells may acquire a more “quiescent-like” gene expression 
profile upon DLL4 and PDGF-BB treatment. This is reflected in the down-
regulation of the activation marker MyoD and in a low but consistent up-
regulation of the quiescence marker Pax7 (no statistical significance 
observed for this gene). This gene expression profile resembles also the one 
observable in freshly isolated satellite cells. We believe this supported the 
improvement in the engraftment efficiency observed in our proof-of-principal 
transplantation experiments. This improved engraftment is also consistent 
with what observed in other studies on Notch-stimulated satellite cells and 
mesoangioblasts (Parker et al., 2012a; Quattrocelli et al., 2014). Consistently 
with our “increased quiescence” theory, treated cells showed also a reduction 
in their proliferation and myogenic potential in vitro. These observations 
complement what previously reported in other studies involving Notch up-
regulation in myogenic progenitors (Parker et al., 2012a; Quattrocelli et al., 
2014; Wen et al., 2012). Our results confirmed also that these phenomena 
are signalling-dependent. However, these variations did not affect the cell 
expansion required to perform in vivo experiments.  
It has to be mentioned that for the reported series of qRT-PCR 
experiments GAPDH has been used as normalizer. Although its use is 
commonly accepted, a recent report from Hildyard and Wells indicated that 
this gene might not retain the same level of expression in differentiating 
myogenic cells and it might not be an ideal gene expression normaliser. For 
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this reason the use of Csnk2a2 and Ap3d1 will be taken into account for 
future experiments involving myogenic cells (Hildyard and Wells, 2014). 
Similarly to bona fide pericytes, treated cells were capable to stabilise 
endothelial networks in vitro. This indicated that the treatment not only 
induced pericyte marker expression, but also that the cells acquired functional 
pericyte properties. As an additional validation experiment, future analyses 
might include in vivo Matrigel plug assays. In this technique, a mixture of 
HUVEC, treated / untreated cells and Matrigel is administered 
subcutaneously to immunodeficient mice to assess the formation of a 
vascular network (Akhtar et al., 2002).  
The migration ability of pericyte-derived mesoangioblasts led to the 
development of a cell therapy protocol recently used in a phase I/II clinical 
trial (EudraCT no. 2011-000176-33). Our results indicated that the pericyte-
like phenotype acquired by our treated satellite cells was reflected also in an 
improved migration through artificial endothelial layers in vitro. In light of 
these results we performed a proof-of-principle intra-arterial transplantation 
experiment. Notably, three weeks after transplantation we have identified 
donor-derived cells that migrated towards the blood vessel walls downstream 
of the injection site and contributed to muscle regeneration.  
With the aim of improving the migration ability observed in treated 
satellite cells even further, a proposed follow up to this project could include 
testing a combination of molecules known to stimulate cell migration such as 
Diprotin A, Adiponectin or SDF1 (Fiaschi et al., 2010; Galvez et al., 2006; 
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Parker et al., 2012b). Moreover, a recent work published by Giannotta, 
Benedetti and colleagues showed that pharmacological inhibition of the 
GTPase Rap1 significantly increase engraftment and migration ability of intra-
arterially transplanted mesoangioblasts impeding the tightening of endothelial 
cell junctions targeting the molecule JAM-A (Giannotta et al., 2014). It is not 
unconceivable that this mechanism, in combination with the strategies 
mentioned above, might also be exploited to improve the migration of cells 
obtained with the protocols detailed in this thesis. 
It will be important, as a follow up of this study, to assess if the Notch / 
PDGF stimulation elicits a similar response in human cells. Human 
myoblasts, isolated on purpose or obtained from bio-banks are currently 
being subjected to the stimulation aiming to investigate their possible fate 
plasticity. A pilot experiment we recently performed treating human myoblast 
indicates that the treatment has no visible effect on morphology, induces an 
up-regulation of the alkaline phosphatase activity (Figure 32A) but appears 
not to alter the myogenic differentiation potential of the cells (Figure 32B). 
Although a more systematic analysis of additional cell population may be 
required, this preliminary experiment suggests that further studies are 
needed to adapt the treatment conditions to human cells. 
If an adaptation of this protocol to human cells will be successful it 
may allow the generation of a novel hybrid human pericyte-like cell type with 
relevance for possible future clinical applications. The ideal cells will harbour, 
upon treatment, the key properties of both pericytes and satellite cells: 
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namely, the ability of crossing the vessel upon systemic delivery combined 
with high myogenic potential and ability to self-renew.	
Figure 32. Assessment of alkaline phosphatase activity and myogenic 
differentiation potential of treated human myoblasts. The panel shows 
the results of a preliminary experiment conducted using one line of human 
myoblasts. A The image shows a staining for the alkaline phosphatase 
activity on untreated and treated human myoblasts (Scale bar: 100um). The 
percentage of AP positive cells is quantified on the right (Untreated 10.96% ± 
0.84 SEM; Treated 65.72% ± 3.05 SEM). B Immunofluorescence staining for 
Myosin Heavy Chain performed on untreated and treated human myoblasts 
subjected to terminal myogenic differentiation assay (Scale bar: 140um). The 
graph depicts the percentage of cells within the  (Untreated 24.03%  ± 1.11 
SEM; Treated 26.86% ± 2.51 SEM). 
The self-renewal potential of satellite cells has been formally demonstrated by 
Rocheteau and colleagues in a rigorous serial transplantation setup 
(Rocheteau et al., 2012). Previous reports from our group indicated that 
pericyte- and mesoangioblast-derived cells repopulate the satellite cell niche 
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and generate Pax7 positive cells during muscle regeneration and upon 
transplantation (Dellavalle et al., 2011; Tedesco et al., 2011). 
Mesoangioblasts were also capable of sustaining long-term engraftment and 
a subsequent round of regeneration upon acute myoinjury (Tedesco et al., 
2011).  
Understanding if pericytes are capable of generating self-renewing 
cells upon transplantation has a crucial importance, considering the impact 
this might have on novel cell therapy protocols arising for the recent 
mesoangioblast-based clinical trial. Moreover, investigating if pericyte-like 
cells possess this property, is also important in light of the results detailed in 
chapter 5 in which satellite cells are shifted towards that lineage. The 
experiments reported in chapter 6 were designed to investigate if 
mesoangioblasts are capable of generating self-renewing satellite-like cells by 
means of serial transplantation assays.  
Wild type mesoangioblasts engrafted the host muscles and generated 
satellite-like cells. It was then possible to re-isolate these cells that re-
engrafted dystrophic muscles and generate single cell clones. We extended 
these findings to genetically corrected mesoangioblasts, which allowed the 
generation of serially transplantable satellite-like cells up to three round of 
transplantation. We subjected the cell population isolated from the third round 
of transplants to single cell cloning and then re-transplanted two of these 
randomly picked clones, with the aim of confirming the potency of 
engraftment also at the clonal level. Genetically corrected mesoangioblasts 
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successfully supported three subsequent round of transplantation and re-
isolation, generating at each round both donor-derived SM/C-2.6-positive 
(satellite) and negative (non-satellite) cells. With the exception of a single 
report from Sacco and colleagues (Sacco et al., 2008), transplantation of a 
single cell in the skeletal muscle is known to be extremely challenging 
(Rocheteau et al., 2012). Experiments using donor-derived single cell clones 
obtained from transplanted muscles could recapitulate the behaviour of a 
single cell, subjected to subsequent rounds of amplification during tissue 
regeneration, indirectly providing indications on the potential of these cells.  
Replicates of the muscles serially transplanted with genetically 
corrected DYS-HAC mesoangioblast have been cryopreserved and are now 
being cryosectioned and analysed by immunofluorescence staining and 
molecular biology techniques (such as qRT-PCR) to evaluate the efficiency of 
the engraftment. This characterisation is part of a project developed under my 
co-supervision by Chrystalla Constantinou (UCL MRes student). 
The main limitation of this set of experiments was the use of cells lines. 
Although these cells have been utilised and characterised from recent 
previous studies, the long-term culture might have introduced a bias in our 
evaluation of their potency. With the aim of overcome this limitation we 
decided to perform a series of serial transplantation experiments using freshly 
isolated cells, obtained crossing the TnAP-CreERT2 mouse with the R26R-
YFP reporter. Isolation of YFP-positive pericytes was performed using the 
FACS sorter but although the cells were viable and positive for the YFP, the 
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weakness of the fluorescence of this reporter, impeded tracing the cells in the 
transplanted muscles.  
To overcome the limitation in the ability to trace the cells, pericytes 
have been recently isolated in the laboratory from TnAP-CreERT2-R26R-
tdTomato mice. These animals were obtained upon crossing the TNAP-
CreERT2 mice with a reporter mouse that carries a tdTomato fluorescent 
cassette, whose fluorescence is brighter than the one of the YFP (Madisen et 
al., 2010; Shaner et al., 2005). With the aim of improving the detection of few 
donor cells in a dystrophic muscle, the freshly isolated TNAP-tdTomato 
pericytes will be transplanted in α-sarcoglycan-null/scid/beige mice (Tedesco 
et al., 2012), excluding the bias of the revertant fibres not present in this 
model.  
Serial transplantation of freshly isolated pericytes will be performed for 
at least three rounds of transplantation / isolation aiming to validate what 
observed with the two mesoangioblast cell lines. A single-cell cloning assay 
will also be performed on the serially transplanted TnAP-tdTomato pericyte-
derived cells to analyse if their clonogenic potential is in line with the 
observations reported in this thesis. Some of these experiments have been 
recently performed under my co-supervision as part of Chrystalla 
Constantinou MRes project. These results will be included as original data in 
her final dissertation.  
The data obtained so far provided indications that mesoangioblast-
derived satellite-like cells are capable of self-renewal in a serial 
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transplantation setup. Notably donor-derived SM/C-2.6-negative myogenic 
cells were present and have been isolated from each isolation experiment 
performed. The generation of pericytes/mesoangioblasts in vivo upon 
transplantation of satellite-like cells cannot therefore be excluded. While the 
possibility of performing serial transplantation experiments with these cells is 
currently under consideration, the characterisation of these negative fractions 
is in the pipeline. If these results will indicate the presence of satellite cell-
derived mesoangioblasts in the negative fractions, the mechanism underlying 
this fate switch will be investigated aiming to dissect the biological relevance 
of this phenomenon.  
Meaningful insights about the mechanisms guiding this fate plasticity in 
vivo will come also from the microarrays performed for the project described 
in chapter 5. These results might provide significant information that will help 
to unveil what rules the homeostatic balance between satellite cells and 
pericytes. Particular attention will be given in comparing the signals in use to 
induce the fate switch in vitro (Notch activation and PDGF-BB) with the ones 
involved in the self-renewal mechanism, aiming to investigate a possible 
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